FDA Calendar

Biotech Stock Catalyst and FDA Calendar for your biotech stock investing. Use our tools on your road to profit in the stock market. Biotech stocks with key binary events/catalysts - FDA Approval/PDUFA, Advisory Committee and Phase 2 & 3 trial data releases dates.

ABBREVIATIONS USED FOR CATALYST DATES:

(1)Q = (First) quarter of calendar year.

(1)H = (First) half of calendar year

YE = "Year end" - used when companies give guidance similar to "by the end of 2019" or "towards the end of 2019".

2018 - The year is used when companies only give guidance as to which year the catalyst is slated for, without mentioned which quarter or half.


Please refer to the "FDA Calendar Glossary" for a list of terms used in the FDA Decision Calendar.

LARGE CAP CATALYSTS - generally only Phase 3 catalysts noted in company presentations and/or earnings releases are shown.

PDUFA DATES - biosimilars and sNDA/sBLA filings and resubmissions are only noted if a PDUFA date has been released by the company. No official PDUFA date = No entry (e.g. Saxagliptin and dapagliflozin resubmission). Standard reviews for NDA/BLA filings use a 10 month estimate following filing acceptance for a NEW MOLECULAR ENTITY if no PDUFA date has been announced.

Pipeline data are current and updated daily! Click on the date for the source of the catalyst.

Refer to the Biotech Historical Catalyst Calendar for completed biotech stock catalysts.


Financial data are delayed 15-35 minutes.

Subscribe HERE to ensure you receive your weekly FREE copy of the BioPharmCatalyst Biotech Stock Watch list and/or our daily option of Biotech Stock Price Movers and Pipeline Database updates


Showing 539 drugs
Ticker Price Drug Stage Catalyst
SGYP
$2.64
+0.24  (+10%)
Trulance (plecanatide)
Constipation-predominant irritable bowel syndrome (IBS-C)
PDUFA
Phase 3 data from first and second trials met primary endpoints - December 9 and 22, 2016. PDUFA date January 24, 2018.
BYSI
$28.21
+2.24  (+8.62%)
Plinabulin (Trial 105)
Prevention of neutropenia
Phase 2/3
Data from Phase 2 part of trial to be presented at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium January 25, 2018.
ARDM
$2.42
+0.13  (+5.67%)
Linhaliq (Pulmaquin)
Non-cystic fibrosis bronchiectasis (non-CF BE).
PDUFA priority review
PDUFA date under priority review January 26, 2018. Phase 3 data released December 1, 2016. One of two trials met primary endpoint. Advisory Committee Meeting January 11, 2018 voted 3-12 against recommending approval.
NVS
$87.00
+0.06  (+0.06%)
Lutathera
Inoperable progressive midgut NETs
PDUFA
CRL issued December 21, 2016. NDA to be resubmission announced July 27, 2017 with new PDUFA date January 26, 2018.
VTGN
$1.32
+0.11  (+9.09%)
AV-101
Adjunctive Treatment Major Depressive Disorder
Phase 2 1H 2019
Phase 2 trial to commence 1H 2018 with top-line data due 1H 2019. Update on trial expected January 29, 2018 at NobleCon14.
KDMN
$5.05
+0.17  (+3.48%)
KD025
Idiopathic pulmonary fibrosis (IPF)
Phase 2 January 2018
Phase 2 data due January 2018.
AMAG
$14.35
+0.5  (+3.61%)
Feraheme
Adults with iron deficiency anemia (IDA)
PDUFA
PDUFA date February 2, 2018 for sNDA filing.
AVEO
$2.97
+0.04  (+1.36%)
Tivozanib + Opdivo
Renal cell cancer (RCC)
Phase 1/2 February 8-10, 2018
Enrollment of Phase 2 portion of Phase 1/2 trial complete with initial Phase 2 data due at Genitourinary Cancers Symposium February 8-10, 2018.
FOLD
$15.97
+0.07  (+0.44%)
ATB200
Pompe Disease
Phase 1/2
Phase 1/2 additional data released February 15, 2017, May 15, 2017 and October 4, 2017. Further update February 8, 2018.
TCON
$2.95
+0.15  (+5.35%)
DE-122 and Lucentis - AVANTE
Wet age-related macular degeneration (Wet-AMD)
Phase 2
Phase 2 AVANTE trial initiation announced July 25, 2017. Phase 1/2 PAVE trial results to be presented February 10, 2018 at Angiogenesis, Exudation and Degeneration Meeting.
GILD
$81.41
+0.43  (+0.53%)
Bictegravir/F/TAF
HIV
PDUFA priority review
PDUFA date under priority review February 12, 2018.
VRX
$22.03
+0.51  (+2.36%)
Plenvu (NER1006)
Bowel cleansing
PDUFA
PDUFA date February 13, 2018.
AMAG
$14.35
+0.5  (+3.61%)
Makena - auto injector
Reduce the risk of preterm birth in women with a singleton pregnancy
PDUFA
sNDA filing announced April 17, 2017. PDUFA date February 14, 2018. 10-month review despite initial expectations of a 6-month review.
ATRS
$2.25
+0  (+0%)
Makena - auto injector
Preterm birth
PDUFA
sNDA filing announced April 17, 2017. PDUFA date February 14, 2018. 10-month review despite initial expectations of a 6-month review
PCRX
$39.35
+0.6  (+1.54%)
EXPAREL
Single-dose injection femoral nerve block for total knee arthroplasty surgery
PDUFA Adcom 2/14/18; PDUFA 4/6/18
Phase 3 data released July 25, 2017. Upper extremity met primary endpoint, lower extremity trial missed endpoint. PDUFA date for sNDA filing set for April 6, 2018. Advisory Committee Meeting February 14-15, 2018.
KURA
$17.45
-0.35  (-1.97%)
Tipifarnib
Head and neck squamous cell carcinomas (HNSCC)
Phase 2 February 15-17, 2018
Presentation of updated data due February 15-17, 2018 at Multidisciplinary Head and Neck Cancers Symposium.
APRI
$2.64
-0.01  (-0.38%)
Vitaros
Erectile dysfunction
PDUFA
PDUFA date for NDA resubmission February 17, 2018.
IMNP
$0.60
+0.01  (+1.79%)
Bertilimumab
Bullous pemphigoid (BP)
Phase 2
Phase 2a late breaking abstract February 17, 2018 at 2018 American Academy of Dermatology (AAD) Annual Meeting.
KMPH
$5.65
-0.01  (-0.09%)
KP201/APAP
Acute pain.
PDUFA
PDUFA date February 23, 2018 - CRL issued June 13, 2016.
AIMT
$38.26
-0.64  (-1.65%)
AR101 PALISADE
Peanut Allergy
Phase 3 February 2018
Phase 3 initiated January 2016. Enrollment completion announced November 28, 2016. Top-line data due February 2018.
AST
$2.40
+0  (+0%)
AST-OPC1 SCiSTAR
Cervical spinal cord injury
Phase 1/2 February 2018
Phase 1/2 six-month top-line data due June 2018 with 12-month data due December 2018. 6-month data from Cohort 3 (AIS-A 20 million-cell cohort) and Cohort 4 (AIS-B 10 million-cell cohort) due February 2018, and the 12-month data from Cohorts 3 and 4 in August 2018.
CRMD
$0.47
-0.02  (-3.45%)
Neutrolin - LOCK-IT 100
Hemodialysis patients with central venous catheters
Phase 3 Early 2018
Phase 3 data due 2H 2018 with interim analysis due early 2018.
MDGL
$129.30
+4.71  (+3.78%)
MGL-3196
Heterozygous familial hypercholesterolemia (HeFH)
Phase 2 Early 2018
Phase 2 top-line data due early 2018.
MRNS
$7.55
+0.72  (+10.54%)
Ganaxolone
Postpartum depression
Phase 2 Early 2018
Phase 2 data due early 2018.
NVAX
$2.14
+0.17  (+8.62%)
NanoFlu vaccine
Influenza
Phase 1/2 Feb 2018
Phase 1/2 initiation announced September 19, 2017 with data due February 2018.
RXII
$4.10
-0.32  (-7.25%)
RXI-109-1501
Retinal scarring
Phase 1/2 Early 2018
Phase 2 completion of enrollment announced June 21, 2017. Data due early 2018.
SRNE
$7.75
+1.35  (+21.09%)
ZTlido (lidocaine patch 1.8%)
Pain associated with post-herpetic neuralgia (PHN)
PDUFA
PDUFA date for NDA resubmission February 28, 2017.
SRRA
$3.22
+0.03  (+0.94%)
SRA737
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
Phase 1 February 2018
Program update February 2018.
VRTX
$161.91
+3.94  (+2.49%)
Tezacaftor (VX-661) / ivacaftor
Cystic fibrosis - Two Copies of the F508del Mutation
PDUFA priority review
Phase 3 data released March 28, 2017 - primary endpoint met. PDUFA date under priority review February 28, 2017.
OTIC
$5.85
+0.17  (+3.08%)
OTIPRIO
Acute otitis externa
PDUFA
Phase 3 trial met primary endpoint - January 5, 2017. PDUFA date for sNDA filing March 2, 2018.
BMY
$63.28
+1  (+1.6%)
Opdivo - 4 week applications
PDUFA
PDUFA date March 5, 2018 for sBLA filings across all approved indications.
PFE
$36.93
-0.01  (-0.03%)
Xeljanz
Ulcerative colitis
PDUFA
sNDA acceptance announced July 13, 2017. 3-month extension announced December 13, 2017.PDUFA date not given. Estimate June 13 using 8 (+3) month timeline. Advisory Committee meeting March 8, 2018.
BIIB
$347.64
+5.23  (+1.52%)
Natalizumab (α4-integrin inhibitor)
Acute ischemic stroke
Phase 2b Early-2018
Phase 2b data due early 2018.
ABIO
$1.65
+0.05  (+3.12%)
Gencaro - GENETIC-AF trial
Chronic Heart Failure
Phase 2b March 2018
Phase 2b completion of enrollment announced August 16, 2017 - top-line data due March 2018.
ACOR
$27.55
+0.35  (+1.28%)
Tozadenant
Parkinson’s disease (PD)
Phase 3 1Q 2018
Noted November 15, 2017 seven cases of sepsis, five of which were fatal. Phase 3 data due 1Q 2018. However, company noted November 20, 2017 that program will be discontinued.
ALT
$1.82
+0  (+0%)
NasoVAX
Flu vaccine
Phase 1/2 1Q 2018
Phase 2 initial data due 1Q 2018.
ANAB
$114.78
-0.15  (-0.12%)
ANB020
Severe adult peanut allergy
Phase 2a 1Q 2018
Phase 2a data due 1Q 2018.
ANTH
$1.42
+0.14  (+10.93%)
Sollpura - RESULT
Exocrine pancreatic insufficiency
Phase 3 1Q 2018
Passed second futility analysis January 22, 2018. Phase 3 data due end 1Q 2018.
ARNA
$35.89
+0.28  (+0.81%)
APD371
Pain associated with Crohn's disease
Phase 2 1Q or 2Q 2018
Phase 2 data due 1Q or 2Q 2018.
ARNA
$35.89
+0.28  (+0.81%)
Etrasimod
Ulcerative colitis
Phase 2 1Q 2018
Phase 2 data due 1Q 2018.
BHVN
$32.06
+0.82  (+2.62%)
Rimegepant
Migraine
Phase 3 1Q 2018
Phase 3 completion of enrollment noted November 27, 2017 with top-line data due 1Q 2018.
BPTH
$0.22
+0.01  (+3.9%)
Prexigebersen
Acute myeloid leukemia (AML)
Phase 2 Early 2018
Phase 2 first patient enrolled November 2016. Interim analysis due early 2018.
CBIO
$21.21
+1.72  (+8.82%)
CB 2679d/ ISU304
Hemophilia B
Phase 1/2 Early 2018
Phase 1/2 interim data to be presented at ASH 2017. Top-line data due early 2018.
CDTX
$7.50
+0.2  (+2.73%)
Rezafungin (CD101) IV - STRIVE
Candidemia
Phase 2 1Q 2018
Phase 2 initiated June 2016. Completion of enrollment announced November 28, 2017. Data due 1Q 2018.
CELG
$102.91
+0.26  (+0.25%)
REVLIMID - AUGMENT NHL-007
Relapsed or Refractory Follicular Lymphoma
Phase 3 1Q 2018
Phase 3 enrolling. Data due 1Q 2018.
CELG
$102.91
+0.26  (+0.25%)
OTEZLA
Ulcerative Colitis
Phase 2 1Q 2018
Phase 2 data to be presented 1Q 2018.
CLSD
$6.22
-0.22  (-3.42%)
Suprachoroidal CLS-TA - PEACHTREE
Macular edema associated with non-infectious uveitis
Phase 3 1Q 2018
Phase 3 completion of enrollment noted August 7, 2017 with preliminary data due 1Q 2018.
CORT
$24.70
+0.72  (+3%)
CORT125134
Cushing’s syndrome
Phase 2 1Q 2018
Phase 2 trial initiated 2Q 2016. Data due 1Q 2018.
CYTK
$9.55
-0.05  (-0.53%)
CK-2127107
Spinal muscular atrophy (SMA)
Phase 2 1Q 2018
Phase 2 initiated January 2016. Baseline data from first cohort released June 5, 2017. Cohort 2 enrollment to be completed in 2017. Data due 1Q 2018.
DERM
$28.21
+0  (+0%)
Olumacostat glasaretil (DRM01)
Acne
Phase 3 1Q 2018
Phase 3 completion of enrollment announced October 5, 2017. Data are due 1Q 2018.
EARS
$0.51
+0.01  (+2%)
Keyzilen (AM-101) - TACTT3
Acute inner ear tinnitus
Phase 3 1Q 2018 - likely February
Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line data 1Q 2018 (likely February).
EDGE
$12.20
-0.2  (-1.62%)
EG-1962
Improving patient outcomes following an aneurysmal subarachnoid hemorrhage (aSAH)
Phase 3 1Q 2018
Phase 3 futility analysis December 30, 2017 noted trial to continue as planned. Interim top-line data due 1Q 2018. Full top-line data due late 2018.
ESPR
$77.93
+0.73  (+0.94%)
Bempedoic Acid - 1002-039
Hypercholesterolemia
Phase 2 1Q 2018
Phase 2 initiation announced July 26, 2017 - data due 1Q 2018.
ESPR
$77.93
+0.73  (+0.94%)
Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046, 1002-047 and 1002-048
Hypercholesterolemia - statin intolerance
Phase 3 March, May and September 2018
Phase 3 initiation of efficacy trials announced January 8, 2017. Data due March, May and September 2018.
EYEG
$1.24
+0.05  (+3.89%)
EGP-437
Ocular inflammation and pain post cataract surgery
Phase 2b 1Q 2018.
Phase 1/2 top-line data released July 2016. Further data released December 5, 2016. Phase 2b commencement of enrollment announced August 1, 2017. Data due 1Q 2018.
FLKS
$3.88
+0.03  (+0.77%)
FLX-787 (Aust)
Multiple Sclerosis
Phase 2 1Q 2018
Phase 2 completion of enrollment announced November 28, 2017 with data due late 1Q 2018.
GALE
$0.26
-0.01  (-5.11%)
NeuVax in combination with Herceptin
Breast cancer - 1+/2+
Phase 2b 1Q 2018
Phase 2b completion of enrollment announced September 28, 2017 - with interim efficacy analysis due 1Q 2018.
GERN
$1.97
+0.05  (+2.6%)
Imetelstat - IMbarkStudy
Myelofibrosis
Phase 2 1Q 2018
Phase 2 clinical hold lifted Nov 2014. Phase 2 initiated September 2015. Internal review conducted September 2016. Low dose discontinued, high dose enrollment suspended. Further internal data review due 1Q 2018.
GILD
$81.41
+0.43  (+0.53%)
GS-9674
Primary sclerosing cholangitis
Phase 2 1Q 2018
Phase 2 primary endpoint analysis due 1Q 2018.
GILD
$81.41
+0.43  (+0.53%)
GS-5745
Gastric Cancer
Phase 3 1Q 2018
Phase 3 futility analysis 3Q 2017. Interim efficacy analysis 1Q 2018.
GILD
$81.41
+0.43  (+0.53%)
GS-9674
Nonalcoholic steatohepatitis (NASH)
Phase 2 1Q 2018
Phase 2 trial to be completed 1Q 2018.
GILD
$81.41
+0.43  (+0.53%)
Entospletinib
Chronic Graft Versus Host Disease (cGVHD)
Phase 2 1Q 2018
Phase 2 interim analysis due 1Q 2018.
GLMD
$10.85
+0.28  (+2.64%)
Aramchol - ARRIVE
HIV-associated lipodystrophy and nonalcoholic fatty liver disease (NAFLD)
Phase 2 1Q 2018
Phase 2 top-line data due 1Q 2018.
GSK
$38.56
+0.36  (+0.94%)
Dolutegravir + lamivudine (GEMINI 2)
HIV
Phase 3 1Q 2018
Phase 3 trial commenced August 2016. Data likely due 1Q 2018.
GSK
$38.56
+0.36  (+0.94%)
Dolutegravir + lamivudine (GEMINI 1)
HIV
Phase 3 1Q 2018
Phase 3 trial commenced August 2016. Data likely due 1Q 2018.
GTHX
$25.35
-0.99  (-3.76%)
Trilaciclib
First-line small-cell lung cancer
Phase 2 1Q 2018
Phase 2a top-line data due 1Q 2018.
GWPH
$133.75
+1.33  (+1%)
Epidiolex
Infantile spasms (IS)
Phase 3 1Q 2018
Phase 3 initiated December 2016. Part A data due 1Q 2018.
GWPH
$133.75
+1.33  (+1%)
GWP42006 (CBDV)
Epilepsy
Phase 2 1Q 2018
Phase 2 initiated May 2015. Data due 1Q 2018.
IMGN
$8.55
+0.52  (+6.47%)
Mirvetuximab soravtansine - FORWARD II
Ovarian cancer and relapsed endometrial cancer
Phase 1/2 1Q 2018
Phase 1b safety data presented at ASCO June 3, 2017. Abstract 5553. Keytruda dose-escalation data 1Q 2018.
IMGN
$8.55
+0.52  (+6.47%)
Mirvetuximab soravtansine - FORWARD I
Cancer - ovarian cancer and relapsed endometrial cancer
Phase 3 1Q 2018
Phase 3 futility analysis 1Q 2018. Enrollment to be completed mid-2018. Top-line data 1H 2019.
IMRN
$7.01
-0.1  (-1.41%)
IMM-124E
Nonalcoholic steatohepatitis (NASH)
Phase 2 1Q 2018
Phase 2 interim analysis July 10, 2017 showed no statistical difference with placebo. Top-line data due 1Q 2018.
MBIO
$12.18
-0.08  (-0.58%)
MB-102
Acute myeloid leukemia
Phase 1 Early 2018
Phase 1 data due early 2018.
MBIO
$12.18
-0.08  (-0.58%)
MB-101
Glioblastoma
Phase 1 Early 2018
Phase 1 data due early 2018.
MBVX
$0.91
+0.03  (+3.95%)
MVT-1075
Pancreatic, colon and lung cancers
Phase 1 1Q 2018
Phase 1 interim data due 1Q 2018.
MBVX
$0.91
+0.03  (+3.95%)
MVT-5873
Pancreatic cancer
Phase 1/2 1Q 2018
Phase 1 ongoing. Interim safety and RECIST data due 1Q 2018.
MCRB
$10.81
+0.24  (+2.27%)
SER-262
Primary Clostridium Difficile infection (CDI)
Phase 1b Early 2018
Phase 1b initiated July 2016. Data due early 2018.
MESO
$5.79
-0.1  (-1.7%)
MPC-150-IM - Class IV
Chronic heart failure (CHF)
Phase 2b 1Q 2018
Phase 2b data due 1Q 2018.
MESO
$5.79
-0.1  (-1.7%)
MSC-100-IV
acute graft versus host disease (aGVHD) in children
Phase 3 1Q 2018
Phase 3 completion of enrollment announced December 20, 2017. Data due 1Q 2018.
MRTX
$26.05
+0.45  (+1.75%)
Mocetinostat and durvalumab
Non-small cell lung cancer (NSCLC)
Phase 2 1Q 2018 - see note below
Phase 2 Stage 1 update 1Q 2018. Stage 1 data due mid-2018.
MYOK
$54.00
+0.05  (+0.09%)
MYK-461 - PIONEER-HCM
Hypertrophic cardiomyopathy (HCM)
Phase 2 1Q 2018
Phase 2 top-line data released August 7, 2017 - primary endpoint met. Data from low dose cohort due 1Q 2018. Phase 3 EXPLORER-HCM trial to be initiated 2Q 2018.
NBIX
$85.19
+4.51  (+5.59%)
Elagolix
Uterine Fibroids
Phase 3 1Q 2018
Phase 3 initiated by partner Abbvie in January 2016. Data due 1Q 2018.
NVO
$57.95
+0.16  (+0.27%)
Semaglutide - oral - PIONEER
Type 2 diabetes
Phase 3 1Q 2018
Phase 3 data due 1Q 2018.
OBSV
$9.64
-0.09  (-0.93%)
OBE001 - IMPLANT2
IVF
Phase 2 1Q 2018
Phase 2 trial did not meet primary endpoint in 2016. Phase 3 completion of patient recruitment announced September 6, 2017. Data due 1Q 2018.
PLX
$0.69
-0.02  (-2.34%)
OPRX-106
Ulcerative Colitis
Phase 2 1Q 2018
Phase 2 completion of enrollment announced November 30, 2017. Interim data released January 2, 2018. Full data due by end of 1Q 2018.
PTGX
$18.92
-0.08  (-0.37%)
PTG-100
Ulcerative colitis
Phase 2b Early 2018
Phase 2b initiation announced January 17, 2017. Interim futility analysis early 2018 with top-line data due 2018.
PTI
$4.26
+0.1  (+2.4%)
PTI-428 + Kalydeco
Cystic fibrosis
Phase 1 1Q 2018
Phase 1 14 Day data due 1Q 2018.
REGN
$375.86
+4.33  (+1.16%)
Cemiplimab
Cutaneous squamous cell carcinoma
Phase 2 1Q 2018
Phase 2 data due 1Q 2018.
REGN
$375.86
+4.33  (+1.16%)
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
Phase 3 1Q 2018
Phase 3 data due 1Q 2018.
RETA
$30.04
+0.25  (+0.83%)
Bardoxolone methyl - LARIAT
Pulmonary hypertension due to interstitial lung disease - PH-ILD
Phase 2 1Q 2018
Phase 2 enrollment commenced January 2017. Data due 1Q 2018.
RETA
$30.04
+0.25  (+0.83%)
Omaveloxolone - MOTOR
Mitochondrial myopathies (MM)
Phase 2 1Q 2018
Phase 2 initial data due 1Q 2018.
RGLS
$1.39
-0.01  (-0.72%)
RG-012
Renal biopsy study in Alport patients
Phase 1/2 1Q 2018
Phase 1/2 data due 1Q 2018.
RNN
$2.41
+0.01  (+0.41%)
RX-3117
Advanced bladder cancer - 3rd line
Phase 2a 1Q 2018
Phase 2a initial presented at ASCO June 4, 2017. Further data due 1Q 2018.
RNN
$2.41
+0.01  (+0.41%)
Archexin
Renal cell carcinoma (RCC) - cancer
Phase 2a 1Q 2018
Phase 2a second stage enrollment commenced February 2016. Data due 1Q 2018.
SMMT
$12.59
+0.42  (+3.45%)
Ezutromid
Duchenne muscular dystrophy
Phase 2 1Q 2018
Phase 2 24-week data due 1Q 2018.
SPHS
$2.32
+0.1  (+4.5%)
Topsalysin (PRX302)
Localized low to intermediate risk prostate cancer
Phase 2 Late-1Q 2018
Phase 2b initial biopsy data due late 1Q 2018.
SPPI
$20.92
+1.89  (+9.93%)
SPI-2012 (ROLONTIS)
Chemotherapy-Induced Neutropenia
Phase 3 1Q 2018
Phase 3 completion of enrollment announced August 1, 2017 with top-line data due 1Q 2018.
TTPH
$6.49
+0.15  (+2.36%)
Eravacycline (TP-434) - IGNITE3
cUTI - complicated urinary tract infections
Phase 3 1Q 2018
Phase 3 trial did not meet endpoints September 2015. Additional Phase 3 trial initiation announced January 17, 2016. Completion of enrollment announced September 11, 2017. Data due 1Q 2018.
VBLT
$7.55
-0.2  (-2.59%)
VB-111
Recurrent glioblastoma (rGBM) cancer
Phase 3 1Q 2018
Phase 3 completion of enrollment announced January 6, 2017. Interim analysis released October 2, 2017 noted trial to continue as planned. Top-line data due 1Q 2018.
VNDA
$15.10
+0.6  (+4.13%)
HETLIOZ (tasimelteon)
Jet Lag Disorder
Phase 2 1Q 2018
Phase 2 data due in 1Q 2018.
VTVT
$5.91
+0.21  (+3.68%)
TTP399
Type 1 Diabetes
Phase 1/2 Early 2018
Phase 1/2 trial initiation announced November 8, 2017. Phase 1b data due early 2018.
VTVT
$5.91
+0.21  (+3.68%)
Azeliragon - STEADFAST
Mild Alzheimer’s disease
Phase 3 Early 2018
Phase 3 initiated 2Q 2015. Part A enrollment completed September 2016. Part B enrollment completion announced June 1, 2017. Data from Part A due early 2018. Part B due late 2018.
VYGR
$20.23
+1.56  (+8.35%)
VY-AADC01
Advanced Parkinson’s disease
Phase 1b 1Q 2018
Phase 1b trial ongoing. Interim data released December 7, 2016. Positive Cohort 3 data released September 6, 2017. Further updated data due 1Q 2018. Phase 2/3 dosing to commence 2Q 2018.
MRK
$61.25
-0.03  (-0.05%)
Keytruda
Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
PDUFA priority review
PDUFA date for sBLA April 3, 2018.
THERF
$6.67
+0.12  (+1.83%)
Ibalizumab
Multi-drug resistant HIV-1
PDUFA
Original PDUFA date January 3, 2018 extended 3 months to April 3. 2018.
CLVS
$60.67
+3.91  (+6.88%)
Rucaparib ARIEL3
Ovarian cancer patients with a BRCA-like mutation
PDUFA priority review
Phase 3 data released June 20 2017 - primary endpoint met. PDUFA date under priority review April 6, 2018.
EIGR
$8.75
-0.1  (-1.13%)
Pegylated Interferon Lambda (LIMT HDV)
Hepatitis delta virus (HDV)
Phase 2 EASL 2018.
Noted July 24, 2017 that enrollment has been completed. Interim data due at EASL April 11-15, 2018.
LLY
$85.44
-0.05  (-0.06%)
Abemaciclib - MONARCH 3
HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC)
PDUFA priority review
Phase 3 interim analysis April 24, 2017 met primary endpoint. Priority review granted October 12, 2017. PDUFA date not announced - estimate April 12, 2018 using 6-month timeline.
BMY
$63.28
+1  (+1.6%)
CM-214 – Opdivo + Yervoy
First-line Renal cell carcinoma (RCC)
PDUFA priority review
Phase 3 trial stopped early due to clear efficacy - trial met co-primary endpoint. HR 0.63. PDUFA under priority review April 16, 2018.
RARE
$53.39
+4.23  (+8.6%)
KRN23 Burosumab
X-Linked Hypophosphatemia (XLH)
PDUFA priority review
Phase 3 data released April 18, 2017 - primary endpoint met. PDUFA date under priority review April 17, 2018. Advisory Committee Meeting not expected.
RIGL
$4.54
+0.31  (+7.32%)
Fostamatinib
Immune Thrombocytopenic Purpura (ITP)
PDUFA
Phase 3 data from the first trial released August 30 2016. Primary endpoint met. Data from second trial did not meet the primary endpoint. PDUFA date April 17, 2018. Noted October 2, 2017 that no Advisory Committee meeting is planned.
NBIX
$85.19
+4.51  (+5.59%)
Elagolix
Endometriosis
PDUFA priority review
First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints. NDA filing announced September 6, 2017. Priority review announced October 27, 2017. Exact PDUFA date not announced. Estimate April 27, 2017 based on 6-month review.
SCMP
$17.90
-0.05  (-0.28%)
Lubiprostone
Pediatric functional constipation
PDUFA
PDUFA date for sNDA under priority review extended by three months to April 28, 2018.
ALKS
$57.62
+0.59  (+1.03%)
ALKS 3831 - ENLIGHTEN-2
Schizophrenia
Phase 3 Fall 2018
Pivotal trial initiated February 2016. Data due fall of 2018.
AMGN
$192.33
+3.05  (+1.61%)
KYPROLIS (ENDEAVOR)
Relapsed Multiple Myeloma
PDUFA
Phase 3 trial met PFS endpoint - March 2015. Announced February 28, 2017 that interim analysis met secondary endpoint of overall survival (OS). PDUFA date for sNDA April 30, 2018.
BTX
$2.64
+0  (+0%)
OpRegen
Dry age-related macular degeneration (AMD)
Phase 1/2 ARVO Conference - Apr 29 - May 03, 2018
Data from first three cohorts to be presented (if accepted) at Association for Research in Vision and Ophthalmology (ARVO) conference Apr 29 - May 03, 2018.
KPTI
$10.27
+0.26  (+2.59%)
Selinexor - STORM
Quadruple Refractory Multiple Myeloma
Phase 2b April 2018
Phase 2b STORM Study Expansion data due April 2018.
NBRV
$6.80
+0.21  (+3.18%)
Lefamulin - LEAP 2
Moderate to severe Community Acquired Bacterial Pneumonia (CABP)
Phase 3 Spring 2018
Phase 3 completion of enrollment announced December 4, 2017 with data due spring 2018.
NVS
$87.00
+0.06  (+0.06%)
Kymriah (CTL019 )- JULIET
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
PDUFA priority review
sBLA filing announced October 31, 2017. No PDUFA date given. Estimate April 30, 2018 using 6-month timeframe following receipt of sBLA by FDA.
PGNX
$6.52
+0.25  (+3.98%)
Azedra
Pheochromocytoma
PDUFA priority review
Phase 2b primary endpoint met - March 2017. PDUFA date under priority review April 30, 2018.
SGEN
$56.29
+2.81  (+5.25%)
ADCETRIS in combination with chemotherapy ECHELON-1
Frontline Hodgkin lymphoma
PDUFA priority review
Phase 3 data released June 26, 2017 - primary endpoint met. sBLA PDUFA date under priority review May 1, 2018.
PTLA
$49.45
-0.18  (-0.37%)
Andexanet alfa
Factor Xa inhibitor reversal agent
PDUFA
CRL August 17 2016. New PDUFA date initially set for February 2, 2018, extended by three months to May 4, 2018.
LPCN
$1.45
+0.09  (+6.61%)
LPCN 1021
Men with low testosterone (Low T)
PDUFA
CRL issued June 2016. NDA resubmitted with PDUFA orginally scheduled for February 8, 2017 but delayed until May 8, 2017 due to submission of additional data. Advisory Committee meeting January 10, 2018 voted 6-13 against approval.
AZN
$35.94
+0.5  (+1.41%)
Tagrisso - FLAURA
First-line lung cancer
PDUFA priority review Estimate mid-2Q 2018
Phase 3 data released July 27, 2017 - PFS improvement noted. Late breaker at ESMO September 9, 2017 showed PFS 18.9 months compared with 10.2 SOC. sNDA awarded priority review - noted December 18, 2017. No PDUFA date given. Estimate 2Q 2018.
AMGN
$192.33
+3.05  (+1.61%)
Erenumab
Migraine
PDUFA
Phase 3 trial met primary endpoint September 2016. PDUFA date May 17, 2018.
NVS
$87.00
+0.06  (+0.06%)
Erenumab
Migraine
PDUFA
Phase 3 trial met primary endpoint September 2016. PDUFA date May 17, 2018.
DOVA
$31.00
+0.1  (+0.32%)
Avatrombopag
Thrombocytopenia in chronic liver disease (CLD) patients
PDUFA priority review
PDUFA date under priority review May 21, 2018.
JNJ
$148.14
+0.78  (+0.52%)
DARZALEX (Daratumumab) - ALCYONE
Frontline multiple myeloma (non-transplant)
PDUFA priority review
PDUFA date under priority review for sBLA of May 21, 2018. LBA at ASH 2017 noted HR 0.50.
BMRN
$91.71
+2.59  (+2.9%)
Pegvaliase
Phenylketonuria (PKU)
PDUFA priority review
Phase 3 data released March 2016. Primary endpoint hit. Key secondary endpoint missed. PDUFA date extended 3 months to May 25, 2018.
REPH
$8.98
+0.05  (+0.55%)
Intravenous (IV) meloxicam
Acute pain following bunionectomy surgery
PDUFA
Phase 3 data from second trial released November 28, 2016. Primary endpoint met. NDA filing announced July 31, 2017. PDUFA date May 26, 2018.
AMGN
$192.33
+3.05  (+1.61%)
Prolia (denosumab)
Glucocorticoid-induced osteoporosis (GIOP)
PDUFA
PDUFA date for sBLA filing May 28, 2017.
TXMD
$6.45
+0.15  (+2.38%)
Yuvvexy - TX-004HR
Moderate-to-severe vaginal pain
PDUFA
CRL announced May 8, 2017. Company noted that FDA cited a lack of long-term endometrial safety data. New PDUFA date May 29, 2018.
ESPR
$77.93
+0.73  (+0.94%)
Bempedoic acid (ETC-1002-040) - Clear Harmony
Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins
Phase 3 May 2018
Phase 3 long-term safety and tolerability trial initiated January 2016. Completion of enrollment announced January 25, 2017. Top-line results due May 2018.
KTOV
$2.35
+0.01  (+0.42%)
KIT-302
Osteoarthritis and Hypertension
PDUFA
PDUFA date May 31, 2018.
NVS
$87.00
+0.06  (+0.06%)
Tafinlar (dabrafenib) and Mekinist (trametinib)
Melanoma with BRAF V600E or V600K mutations
PDUFA priority review Estimate mid-2Q 2018
Priority review received December 22, 2017. No PDUFA date given. Estimate mid-2Q 2018.
IDRA
$2.17
-0.38  (-14.91%)
IMO-2125 + ipilimumab - ILLUMINATE 204
Cancer - melanoma
Phase 2 ASCO 2018
Phase 1/2 data released September 10, 2017. 6/9 disease control with one CR. Further data due around ASCO June 2018. Phase 3 trial to be initiated 1Q 2018.
VRX
$22.03
+0.51  (+2.36%)
IDP-118
Psoriasis
PDUFA
PDUFA date June 18, 2018.
SCPH
$12.26
+0.07  (+0.57%)
Furoscix
Heart failure
PDUFA
PDUFA June 23, 2018. Phase 3 trial did not meet FDA’s prespecified performance criteria.
AKAO
$11.54
+0  (+0%)
Plazomicin
Complicated urinary tract infections (cUTI)
PDUFA priority review
Phase 3 data released December 12, 2016 - primary endpoint met. PDUFA date under priority review June 25, 2018.
GWPH
$133.75
+1.33  (+1%)
Epidiolex
Dravet Syndrome and Lennox-Gastaut syndrome
PDUFA priority review
PDUFA date under priority review June 27, 2018. Expects Advisory Committee Meeting to be scheduled.
ABBV
$106.49
+1.85  (+1.76%)
Rova-T (TRINITY)
Third-line Small Cell Lung Cancer
Phase 2 2Q 2018
Phase 2 pivotal data 2Q 2018.
ACRS
$24.79
+0.39  (+1.59%)
ATI-50002 - PK/safety
Alopecia areata
Phase 2 1H 2018
Phase 2 data due 1H 2018.
ACRS
$24.79
+0.39  (+1.59%)
ATI-50002 - open label
Alopecia areata
Phase 2 1H 2018
Phase 2 data due 1H 2018.
AGN
$188.15
+6.82  (+3.76%)
Brimo DDS
Atrophic Age-related macular degeneration (AMD)
Phase 2 1H 2018
Phase 2 top-line data due 1H 2018.
AGN
$188.15
+6.82  (+3.76%)
ATOGEPANT
Prophylaxis (migraine)
Phase 2b 1H 2018
Phase 2b top-line data due 1H 2018.
AGN
$188.15
+6.82  (+3.76%)
UBROGEPANT
Acute (migraine)
Phase 3 1H 2018
Phase 3 initiated July 2016. Data due 1H 2018.
AGN
$188.15
+6.82  (+3.76%)
ESMYA (ulipristal acetate)
Uterine Fibroids
PDUFA 1H 2018
Phase 3 data released January 18, 2017 - endpoints met. PDUFA date 1H 2018 - exact date not provided.
ALRN
$9.32
+0.11  (+1.19%)
ALRN-6924
Peripheral T-cell lymphoma (PTCL)
Phase 2a 1H 2018
Phase 2a interim data due 1H 2018.
ANAB
$114.78
-0.15  (-0.12%)
ANB020
Severe adult eosinophilic asthma
Phase 2a 2Q 2018
Phase 2a data due 2Q 2018.
ANIK
$59.36
+0.33  (+0.55%)
Cingal
Osteoarthritis
Phase 3 1H 2018
Phase 3 completion of enrollment announced October 25, 2017. Trial to be completed 1H 2018.
APLS
$19.00
+0.1  (+0.52%)
APL-2 IV - FILLY
Geographic atrophy (GA)
Phase 3 1H 2018
Phase 3 trial to commence 2H 2018. Phase 2 18 month safety & efficacy data due 1H 2018.
ARGS
$2.18
+0.01  (+0.46%)
rocapuldencel-T (AGS-003) ADAPT Trial
Metastatic renal cell carcinoma (mRCC)
Phase 3 1H 2018
Phase 3 trial recommended be discontinued for futility - February 22, 2016. Noted August 9, 2017 that it intends to continue the ADAPT trial until at least the pre-specified number of 290 events occurs. Noted further on November 9, 2017 that it intends to request to the FDA to increase the number beyond 290. Interim analysis 1H 2018.
ARGS
$2.18
+0.01  (+0.46%)
AGS-004 and vorinostat
HIV
Phase 1 1H 2018
Decision to open planned investigator-initiated Phase 2 clinical trial for long-term viral control in pediatric patients expected in 1H 2018 pending positive data from Phase 1 trial.
ARRY
$15.56
+2.42  (+18.41%)
Binimetinib - COLUMBUS
BRAF mutant melanoma cancer
PDUFA
Phase 3 data released September 26, 2016 met primary endpoint. PDUFA date June 30, 2018 - no Adcom anticipated.
ASNS
$13.98
+0.35  (+2.56%)
ASN100
Staphylococcus aureus
Phase 2 1H 2018
Phase 2 top-line data due 2H 2018. Power analysis due 1H 2018.
AVEO
$2.97
+0.04  (+1.36%)
TIVO-3 - tivozanib
Third line treatment of patients with renal cell cancer
Phase 3 2Q 2018
Phase 3 completion of enrollment noted June 20, 2017. Futility analysis released October 6, 2017 - trial to continue as planned. Top-line data due 2Q 2018.
AVIR
$0.62
-0.05  (-8.16%)
BTA074 5% topical gel
Condyloma
Phase 2 2Q 2018
Phase 2 completion of enrollment announced November 29, 2017 with data due 2Q 2018.
AXON
$2.20
+0.17  (+8.37%)
Nelotanserin
DLB patients experiencing REM Behavior Disorder (RBD)
Phase 2 2Q 2018
Phase 2 data due 2Q 2018.
AXSM
$3.10
+0.15  (+5.08%)
AXS-05 STRIDE-1
Treatment resistant depression
Phase 3 1H 2018
Phase 3 initiated March 2016. Top-line data due 1H 2018.
AZN
$35.94
+0.5  (+1.41%)
Selumetinib - ASTRA
Thyroid cancer
Phase 3 1H 2018
Phase 3 data due 1H 2018.
AZN
$35.94
+0.5  (+1.41%)
PT010
Chronic obstructive pulmonary disease (COPD)
Phase 3 1H 2018
Phase 3 data due 1H 2018.
AZN
$35.94
+0.5  (+1.41%)
Lynparza
First-line ovarian cancer
Phase 3 1H 2018
Phase 3 data due 1H 2018.
AZN
$35.94
+0.5  (+1.41%)
Durvalumab +/- tremelimumab (MYSTIC)
Lung cancer
Phase 3 1H 2018
Phase 3 data released July 27, 2017 - primary endpoint not met. Overall survival data due 1H 2018.
AZN
$35.94
+0.5  (+1.41%)
Durvalumab +/- tremelimumab (KESTREL)
Head & neck cancer
Phase 3 1H 2018
Phase 3 data due 1H 2018.
AZN
$35.94
+0.5  (+1.41%)
Durvalumab +/- tremelimumab (EAGLE)
Head & neck cancer
Phase 3 1H 2018
Phase 3 data due 1H 2018.
AZN
$35.94
+0.5  (+1.41%)
Durvalumab +/- tremelimumab (ARCTIC)
Lung cancer
Phase 3 1H 2018
Phase 3 data 1H 2018.
BMY
$63.28
+1  (+1.6%)
CM-714 Opdivo + Yervoy
First-line Head and Neck Cancer
Phase 3 1H 2018
Phase 3 data due 1H 2018.
BMY
$63.28
+1  (+1.6%)
CM-511 – Opdivo + Yervoy
First-line Melanoma
Phase 3 1H 2018
Phase 3 data due 1H 2018.
BMY
$63.28
+1  (+1.6%)
CM-331– Opdivo
Second-line Small cell lung cancer (SCLC)
Phase 3 1H 2018
Phase 3 data due 1H 2018.
BMY
$63.28
+1  (+1.6%)
CM-227 – Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 3 1H 2018
Phase 3 data due 1H 2018.
BMY
$63.28
+1  (+1.6%)
CM-548 - Opdivo+SOC
First-line Glioblastoma (GBM) cancer
Phase 2 1H 2018
Phase 2 data due 1H 2018.
BOLD
$37.31
-0.56  (-1.46%)
AT342 - VALENS
Crigler-Najjar
Phase 1/2 2Q 2018
Phase 1/2 preliminary data due 2Q 2018.
CBIO
$21.21
+1.72  (+8.82%)
Marzeptacog alfa
Hemophilia
Phase 2 1H 2018
Phase 2 commencement of Part 2 of Phase 2/3 trial announced January 4, 2018. Interim data due 1H 2018.
CKPT
$4.69
+0.04  (+0.81%)
CK-101
Non-small cell lung cancer (NSCLC) and other solid tumors
Phase 1/2 1H 2018
Potential clinical update 1H 2018.
CLDX
$2.81
+0.05  (+1.81%)
Glembatumumab vedotin
Metastatic triple negative breast cancers that overexpress gpNMB
Phase 2b 2Q 2018
Phase 2b completion of enrollment announced August 23, 2017. Data 2Q 2018.
CLSD
$6.22
-0.22  (-3.42%)
Suprachoroidal CLS-TA - TYBEE
Diabetic Macula Edema (DME)
Phase 2 2Q 2018
Phase 2 completion of enrollment announced October 24, 2017 with preliminary data 2Q 2018.
CLSD
$6.22
-0.22  (-3.42%)
Suprachoroidal CLS-TA - HULK
Diabetic macular edema (DME)
Phase 1/2 2Q 2018
Phase 1/2 enrollment completion announced April 20, 2017. Preliminary data due 2Q 2018.
CNAT
$4.97
+0.26  (+5.52%)
Emricasan
Liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT)
Phase 2b 1H 2018
Phase 2b initiated May 2014. Topline data due 1H 2018.
CORI
$13.79
+0.16  (+1.17%)
Corplex Donepezil
Alzheimer's disease
Phase 1 1H 2018
Pilot bioequivalence data due released May 11, 2017. Pivotal trial commenced fall of 2017 with preliminary data due 1H 2018.
CPRX
$3.62
-0.13  (-3.47%)
Firdapse
Congenital Myasthenic Syndromes (CMS)
Phase 3 1H 2018
Phase 3 data due 1H 2018.
CTIC
$3.37
-0.13  (-3.72%)
PIXUVRI - PIX306 Trial
B-cell non-Hodgkin lymphoma
Phase 3 1H 2018
Phase 3 data due 1H 2018.
DBVT
$26.31
+1.26  (+5.02%)
Viaskin Milk
Cow’s milk protein allergy (CMPA)
Phase 2b 1H 2018
Phase 2b data due 1H 2018.
DERM
$28.21
+0  (+0%)
Glycopyrronium tosylate (DRM04)
Primary axillary hyperhidrosis
PDUFA
PDUFA date June 30, 2018.
DNLI
$21.56
+1.8  (+9.1%)
DNL201
Parkinson’s disease
Phase 1 1H 2018
Phase 1 data due 1H 2018.
EXEL
$29.44
+1.44  (+5.14%)
IMblaze370 - cobimetinib and atezolizumab
Third-line advanced or metastatic colorectal cancer
Phase 3 1H 2018
Phase 3 data due 1H 2018.
EYEG
$1.24
+0.05  (+3.89%)
EGP-437
Non-infectious anterior uveitis
Phase 3 2Q 2018
Phase 3 top-line data due 2Q 2018.
FBIO
$3.96
+0  (+0%)
CEVA101
Severe Traumatic Brain Injury
Phase 2 1H 2018
Phase 2 data in children due 1H 2018.
FBIO
$3.96
+0  (+0%)
Pepvax vaccine
Cytomegalovirus (CMV)
Phase 2 1H 2018
Phase 2 data due 1H 2018.
FBIO
$3.96
+0  (+0%)
IV Tramadol
Post-operative Pain
Phase 3 2Q 2018
Phase 3 initiation announced September 27, 2017 with data due 2Q 2018.
GEMP
$9.76
+1.59  (+19.46%)
Gemcabene - INDIGO-1
Severe Hypertriglyceridemia (SHTG)
Phase 2b 2Q 2018
Phase 2b completion of enrollment announced January 17, 2018 with data due 2Q 2018.
GILD
$81.41
+0.43  (+0.53%)
Selonsertib (GS-4997)
Alcoholic Hepatitis
Phase 2 2Q 2018
Phase 2 trial to be completed 2Q 2018.
GLMD
$10.85
+0.28  (+2.64%)
Aramchol - ARREST
Non-Alcoholic Steatohepatitis (NASH)
Phase 2b 2Q 2018
Phase 2b data due 2Q 2018.
GLPG
$115.77
+3.33  (+2.96%)
GLPG2737 - PELICAN
Adult CF patients who are homozygous for the Class II F508del mutation
Phase 2 1H 2018
Phase 2 top-line data due 1H 2018.
GLPG
$115.77
+3.33  (+2.96%)
Filgotinib - TORTUGA
Ankylosing spondylitis
Phase 2 2Q 2018
Phase 2 initiation announced April 4, 2017. Trial to be completed 2Q 2018.
GLPG
$115.77
+3.33  (+2.96%)
Filgotinib - EQUATOR
Psoriatic arthritis
Phase 2 2Q 2018
Phase 2 initiation announced April 4, 2017. Trial to be completed 2Q 2018.
GTHX
$25.35
-0.99  (-3.76%)
G1T38 plus Faslodex
ER+ breast cancer
Phase 1b 2Q 2018
Phase 1b preliminary data due 2Q 2018.
HRTX
$23.45
+0.25  (+1.07%)
HTX-011
Bunionectomy and hernia repair
Phase 3 1H 2018
Phase 3 top-line data due 1H 2018.
IDRA
$2.17
-0.38  (-14.91%)
IMO-8400
Dermatomyositis
Phase 2 2Q 2018
Phase 2 initiated November 2015. Enrollment completed 3Q 2017 with data due 2Q 2018.
IMMP
$1.88
+0.02  (+1.33%)
Eftilagimod alpha and Keytruda
Melanoma
Phase 1 1H 2018
Phase 1 data from all three cohorts is expected 1H 2018.
INCY
$94.08
+0.92  (+0.98%)
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Phase 3 1H 2018
Phase 3 initiated June 2016. Initial data due 1H 2018.
INCY
$94.08
+0.92  (+0.98%)
Ruxolitinib - REACH 1
Graft versus host disease
Phase 3 1H 2018
Phase 2 pivotal trial dosing initiation announced December 30, 2016. Data due 1H 2018.
INFI
$2.19
+0.15  (+7.35%)
IPI-549 + Nivolumab
Solid tumors
Phase 1 2Q 2018
Presentation at SITC November 10, 2017. Further initial data due 2Q 2018.
IONS
$51.70
+1.48  (+2.94%)
IONIS-HTT Rx
Huntington's Disease
Phase 1/2 1H 2018
Phase 1/2 data to be presented 1H 2018.
JNCE
$22.22
+0.46  (+2.11%)
JTX-2011
Solid tumors - Cancer
Phase 1/2 1H 2018
Phase 1/2 trial initiated September 2017.Phase 2 arm initiation announced April 21, 2017. Efficacy data due 1H 2018.
JNJ
$148.14
+0.78  (+0.52%)
Esketamine
Treatment resistant depression
Phase 3 2018
Phase 3 ongoing. Data and regulatory filings likely due 2018.
KMPH
$5.65
-0.01  (-0.09%)
KP415
ADHD
Phase 3 2Q 2018
Pivotal efficacy trial initiation announced January 8, 2018. Completion of trial due 2Q 2018.
KURA
$17.45
-0.35  (-1.97%)
Tipifarnib
Lower risk myelodysplastic syndromes (MDS) - cancer
Phase 2 1H 2018
Phase 2 top-line data due 1H 2018.
MACK
$11.12
+0.3  (+2.77%)
MM-141 - CARRIE
Cancer - front line pancreatic cancer
Phase 2 1H 2018
Phase 2 completion of enrollment announced June 19, 2017. Data due 1H 2018.
MDWD
$4.45
+0  (+0%)
NexoBrid
Severe burns
Phase 3 1H 2018
Phase 3 initiated mid April 2015. Data due 1H 2018.
MEIP
$2.25
+0.05  (+2.27%)
Pracinostat in combination with Vidaza
High-risk Myelodysplastic Syndrome (MDS)
Phase 2 1H 2018
Phase 2 commencement of dosing announced June 14, 2017 - data from first stage due 1H 2018.
MGNX
$19.42
+0.23  (+1.19%)
Margetuximab in combination with pembrolizumab
Gastric cancer
Phase 2 1H 2018
Phase 2 data due 1H 2018.
MTNB
$1.18
+0  (+0%)
MAT2501
Non-tuberculous mycobacterium (NTM)
Phase 2 2Q 2018
Phase 2 trial to be initiated 2H 2018. Data from PK/tolerability trial due 2Q 2018.
NBIX
$85.19
+4.51  (+5.59%)
NBI-74788
Congenital Adrenal Hyperplasia (CAH) - adults
Phase 2a 1H 2018
Phase 2a data due 1H 2018.
NLNK
$8.56
-0.06  (-0.7%)
Indoximod + gemcitabine and nab-paclitaxel
Pancreatic cancer
Phase 2 1H 2018
Phase 2 data due 1H 2018.
NVS
$87.00
+0.06  (+0.06%)
LEE011: MONALEESA-3
Breast cancer - (post-menopausal)
Phase 3 2Q 2018
Phase 3 trial completion 4Q 2017, publication due 2Q 2018.
PBYI
$93.95
+2.35  (+2.56%)
Neratinib
Third-line HER2-positive metastatic breast cancer
Phase 3 1H 2018
Phase 3 data due 1H 2018.
PFNX
$3.28
+0.08  (+2.5%)
PF708 and Forteo
Osteoporosis
Phase 3 1H 2018
Top-line immunogenicity data due 1H 2018.
PRTA
$41.51
+1.99  (+5.03%)
NEOD001 PRONTO
Previously-treated patients with AL amyloidosis and persistent cardiac dysfunction
Phase 2b 2Q 2018
Phase 2b data due 2Q 2018.
PSTI
$1.52
+0.01  (+0.65%)
PLX-PAD (stem cells)
Intermittent claudication, or IC
Phase 2 1H 2018
Phase 2 put on clinical hold Jun 2013. Lifted Sept 2013. Enrollment completed May 2016. Data are due 1H 2018.
RNN
$2.41
+0.01  (+0.41%)
Supinoxin
Triple negative breast cancer
Phase 2a 2Q 2018
Phase 2a data due 2Q 2018.
RXDX
$26.90
-0.05  (-0.19%)
RXDX-105
Solid tumors - cancer
Phase 1b 1H 2018
Phase 1b data update 1H 2018.
RXII
$4.10
-0.32  (-7.25%)
Samcyprone - RXI-SCP-1502
Cutaneous warts
Phase 2 1Q/2Q 2018
Phase 2 enrollment completed - noted September 6, 2017. Full readouts due 1Q/2Q 2018.
RYTM
$29.04
+1.14  (+4.12%)
Setmelanotide
POMC Heterozygous Deficiency Obesity, Alstrom Syndrome, POMC Epigenetic Disorders
Phase 2 1H 2018
Phase 2 data due 1H 2018.
SAGE
$168.67
-0.79  (-0.47%)
SAGE-217
Postpartum depression (PPD)
Phase 2 2Q 2018
Phase 2 initiation announced December 4Q 2016. Data due 2Q 2018.
SBBP
$8.45
-0.1  (-1.17%)
COR-003 (levoketoconazole) - SONICS
Endogenous Cushing’s syndrome
Phase 3 2Q 2018
Phase 3 completion of enrollment announced June 27, 2017 with top-line data due 2Q 2018.
SGMO
$19.40
+1.65  (+9.29%)
SB-525 cDNA gene therapy
Hemophilia A
Phase 1/2 1H 2018
Phase 1/2 enrolling. Data due 1H 2018.
SGMO
$19.40
+1.65  (+9.29%)
SB-318
MPS Type 1
Phase 1/2 1H 2018
Phase 1/2 data due 1H 2018.
SGMO
$19.40
+1.65  (+9.29%)
SB-913 - CHAMPIONS
MPS Type 2
Phase 1/2 1H 2018
Phase 1/2 commencement of dosing announced November 15, 2017 with data due 1H 2018.
SNDX
$10.82
+0.65  (+6.39%)
Entinostat plus Keytruda - ENCORE 601
Recurrent non-small cell lung cancer (NSCLC)
Phase 1/2 1H 2018
Phase 2 trial to advance to second stage of trial - noted May 16, 2017. Updated data due 1H 2018.
SNDX
$10.82
+0.65  (+6.39%)
E2112
HR+, HER2- breast cancer
Phase 3 1H 2018
Phase 3 PFS data due by the end of 1H 2018.
SNGX
$2.17
+0.04  (+1.87%)
SGX301 (synthetic hypericin)
Cutaneous T-Cell Lymphoma (CTCL) cancer
Phase 3 1H 2018
Phase 3 data due 1H 2018.
SPRO
$12.20
+0.14  (+1.16%)
SPR741
Healthy Volunteers (safety trial)
Phase 1b 1H 2018
Phase 1b top-line data due 1H 2018.
SVRA
$13.04
+0.04  (+0.3%)
Aironite - INDIE
Pulmonary hypertension (PH)
Phase 2 1H 2018
Phase 2 completion of enrollment announced October 18, 2017. Data due 1H 2018.
TBPH
$29.64
+1.32  (+4.66%)
TD-9855
nOH
Phase 2a 1H 2018
Phase 2a data due 1H 2018.
TCON
$2.95
+0.15  (+5.35%)
TRC253
Prostate cancer
Phase 1/2 1H 2018
Phase 1/2 dosing commenced May 24, 2017. Completion of dose escalation phase due 1H 2018.
TCON
$2.95
+0.15  (+5.35%)
TRC105 and Inlyta
Renal Cell Carcinoma (RCC) - cancer
Phase 2 1H 2018
Phase 2 initiated Dec 2014. Completion of enrollment announced September 7, 2017. Top-line PFS data due 1H 2018.
TGTX
$10.25
+0.9  (+9.62%)
TG-1101 and TGR-1202 - UNITY-CLL study
Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin's Lymphoma (NHL)
Phase 3 2Q 2018
Phase 3 completion of full enrollment announced October 16, 2017 with top-line data due 2Q 2018.
TOCA
$13.63
-0.49  (-3.48%)
Toca 511 & Toca FC
Recurrent brain cancer
Phase 2/3 1H 2018
Data from Phase 2 portion are due 1H 2018.
TPIV
$4.04
+0.08  (+2.02%)
TPIV200
Second line triple-negative breast cancer (TNBC)
Phase 2 1H 2018
Phase 2 enrollment commenced - noted December 13, 2017. Interim data due 1H 2018.
TSRO
$68.22
+4.3  (+6.74%)
Niraparib and Keytruda (TOPACIO)
Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 1H 2018
Phase 1/2 enrolling. Initial data presented at ASCO investor event. ORR 4/13 patients. Further data due 1H 2018.
TTNP
$1.35
+0.07  (+5.88%)
Ropinirole implant
Parkinson's disease
Phase 1/2 1H 2018
Phase 1/2 treatment has commenced - noted October 11, 2017. Data from first patient cohort due 1H 2018.
VICL
$1.44
-0.43  (-23%)
VCL-HB01 HSV-2 Therapeutic Vaccine
Genital Herpes in Adults
Phase 2 2Q 2018
Phase 2 trial initiated September 2016. Enrollment completion announced April 19, 2017 with data due 2Q 2018.
VKTX
$4.84
+0.19  (+4.08%)
VK2809
Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Phase 2 1H 2018
Phase 2 trial to be completed 1H 2018.
VRNA
$13.25
+0.41  (+3.19%)
RPL554
Cystic fibrosis
Phase 2a 1H 2018
Phase 2a dosing initiated April 2017. Data due 1H 2018.
XLRN
$44.50
+1.46  (+3.39%)
ACE-083
Charcot-Marie-Tooth disease (CMT)
Phase 2 1H 2018
Phase 2 commencement of dosing announced August 1, 2017. Preliminary data due 1H 2018.
ZEAL
$15.32
+0.27  (+1.79%)
Dasiglucagon
Severe hypoglycemia in diabetes
Phase 3 2Q 2018
Phase 3 trial initiated July 2017 with data due 2Q 2018.
ZGNX
$37.60
+1.65  (+4.58%)
ZX008 - Study 1504
Dravet syndrom
Phase 3 2Q 2018
Phase 3 data due 2Q 2018.
IONS
$51.70
+1.48  (+2.94%)
Inotersen (IONIS-TTRRx)
NEURO-TTR - familial amyloid polyneuropathy (FAP).
PDUFA priority review
Phase 3 data released May 15, 2017 - primary endpoint met but with safety concerns. Data presented November 2, 2017. PDUFA date under priority review July 6, 2018.
DRRX
$1.25
+0.05  (+4.16%)
RBP-7000
Schizophrenia
PDUFA
PDUFA date July 28, 2017.
INSY
$9.59
+0.9  (+10.35%)
Buprenorphine
Moderate to severe postoperative pain after bunionectomy
PDUFA
Phase 3 data met primary endpoints - August 2016. PDUFA date July 28, 2018. Data to be submitted 1Q 2018 from safety trial, which might impact on PDUFA date (i.e. possible extension).
ALNY
$131.00
+6.17  (+4.94%)
Givosiran
Acute hepatic porphyrias
Phase 3 Mid-2018
Phase 3 trial initation announced November 7, 2017 with interim analysis data available in mid-2018.
ALXN
$123.67
+2.62  (+2.16%)
Eculizumab
Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase 3 Mid-2018
Phase 3 enrollment to be completed in 2017 with data due mid-2018.
ATNX
$16.34
-0.99  (-5.72%)
Oraxol
Metastatic breast cancer
Phase 3 Mid-2018
Phase 3 second interim analysis due mid-2018.
BLRX
$1.06
-0.03  (-2.76%)
BL-8040
Stem-cell mobilization for allogeneic transplantation
Phase 2 Mid-2018
Phase 2 top-line data due by mid-2018.
CMTX
$10.00
+0  (+0%)
CX-072
Phase 2 Mid-2018
Phase 1/2 initial data due mid-2018.
CTMX
$26.30
+0.75  (+2.93%)
CX 072
Solid tumors
Phase 1/2 Mid-2018
Phase 1/2 initial data due mid-2018.
EBIO
$0.88
+0.06  (+7.29%)
Vicinium
Non-muscle invasive bladder cancer (NMIBC)
Phase 3 Mid-2018
Phase 3 top-line data (3-month) due mid-2018 and 12-month data due 2Q 2019.
FOMX
$6.60
+0.19  (+2.96%)
FMX103
Papulopustular rosacea
Phase 3 Mid-2018
Phase 2 top-line data released September 12, 2016. Endpoints met. Phase 3 top-line data due mid-2018.
FOMX
$6.60
+0.19  (+2.96%)
FMX101 - FX2017-22
Acne
Phase 3 Mid-2018
Phase 3 data released March 27, 2017 - three of four primary endpoints met across two trials. Third Phase 3 trial data due mid-2018.
GNMX
$1.52
+0.02  (+1.33%)
AEVI-001 (NFC-1)
ADHD - 9-Gene subset
Phase 2 Mid-2018
Phase 2 data due mid-2018.
GNMX
$1.52
+0.02  (+1.33%)
AEVI-002 (Anti-LIGHT mAb)
Pediatric onset Crohn's disease
Phase 1/2 Mid-2018
Phase 1/2 data due mid-2018.
JUNO
$86.00
+18.19  (+26.82%)
Lico-cel (CD-19 JCAR017) - TRANSCEND
r/r B cell non-Hodgkin lymphoma - cancer
Phase 1/2 2018
Pivotal data due 2018 together with potential BLA filing 2H 2018.
LLY
$85.44
-0.05  (-0.06%)
Ramucirumab
Second-line bladder cancer
Phase 3 Mid-2018
Phase 3 PFS data released May 31, 2017 - primary endpoint met. Final OS results are currently expected in mid-2018.
MRTX
$26.05
+0.45  (+1.75%)
Sitravatinib plus nivolumab
Non-small cell lung cancer (NSCLC)
Phase 2 Mid-2018
Phase 2 data due by mid-2018.
OBSV
$9.64
-0.09  (-0.93%)
OBE2109 - EDELWEISS
Endometriosis
Phase 2b Mid-2018
Phase 2b data due mid-2018.
PULM
$1.45
-0.03  (-2.03%)
Pulmazole (PUR1900)
Allergic bronchopulmonary aspergillosis in patients with asthma.
Phase 1 Mid-2018
Phase 1 dosing to commence early February with data due mid-2018 with Phase 2a trial to be initiated 4Q 2018.
RDHL
$5.33
+0.09  (+1.71%)
RHB-104 MAP US
Crohn’s disease
Phase 3 Mid-2018
Phase 3 enrollment completion announced November 9, 2017 with data due mid-2018.
SCYX
$1.86
+0.01  (+0.54%)
SCY-078 - oral
Vulvovaginal candidiasis (VVC)
Phase 2b Mid-2018
Phase 2b initiation of dosing announced August 3, 2017 - data due mid-2018.
SNSS
$4.38
+0.14  (+3.3%)
SNS-062
Advanced B-Cell Malignancies
Phase 1/2 Mid-2018
Phase 1/2 initiation of dosing announced July 18, 2017. Interim data due mid-2018.
SPRO
$12.20
+0.14  (+1.16%)
SPR994
Healthy Volunteers (safety trial)
Phase 1 Mid-2018
Phase 1 data due mid-2018. Phase 3 trial to be initiated 2H 2018 pending positive data from Phase 1 trial.
SRPT
$65.65
+3.27  (+5.24%)
SRP-5051
Duchenne muscular dystrophy
Phase 1/2 Mid-2018
Phase 1/2a trial initiated November 2018. Multi-dose efficacy portion of study to initiate by mid-2018 or as soon as a therapeutic dose has been identified.
VRNA
$13.25
+0.41  (+3.19%)
RPL554
COPD
Phase 2b Mid-2018
Phase 2a data due 4Q 2017. Phase 2b trial planned for 2H 2017 with data due mid-2018.
VTGN
$1.32
+0.11  (+9.09%)
AV-101
Monotherapy Treatment Major Depressive Disorder
Phase 2 Mid-2018.
Phase 2 top-line data due mid-2018.
XLRN
$44.50
+1.46  (+3.39%)
Luspatercept - BELIEVE
b -thalassemia
Phase 3 Mid-2018
Phase 3 enrollment completion announced June 1, 2017 with data due mid-2018.
XLRN
$44.50
+1.46  (+3.39%)
Luspatercept - MEDALIST
Myelodysplastic syndromes (MDS) cancer
Phase 3 Mid-2018
Phase 3 enrollment completion announced June 1, 2017 with data due mid-2018.
ZFGN
$5.90
-0.15  (-2.48%)
ZGN-1061
Diabetes
Phase 2 Mid-2018
Phase 2 top-line data due mid-2018.
REGN
$375.86
+4.33  (+1.16%)
EYLEA
Wet AMD
PDUFA
PDUFA date for sBLA August 11, 2018 - 12-week dosing.
VRX
$22.03
+0.51  (+2.36%)
IDP-121
Acne
PDUFA
PDUFA date August 26, 2018.
AKCA
$18.53
+0.63  (+3.51%)
Volanesorsen - APPROACH
Familial chylomicronemia syndrome (FCS)
PDUFA
PDUFA date August 30, 2017.
AGLE
$7.40
+0.65  (+9.63%)
AEB1102
Arginase I deficiency
Phase 1/2 3Q 2018
Phase 1/2 top-line data due 3Q 2018.
AGTC
$4.15
+0.05  (+1.21%)
rAAV-hRS1
X-linked retinoschisis (XLRS)
Phase 1/2 3Q 2018 est.
Phase 1/2 completion of enrollment due 1Q 2018 with data due after the last patient has been followed for six months (est 3Q 2018).
AMRN
$4.04
+0.07  (+1.76%)
Vascepa REDUCE-IT outcomes trial
High Triglycerides With Mixed Dyslipidemia
3Q 2018
Interim analysis announced September 12, 2016 - trial to proceed. Second interim analysis August 14, 2017 also recommended trial to continue. Final patient visits to commence March 2018 with data due 3Q 2018.
AQXP
$12.24
+0.49  (+4.17%)
AQX-1125 LEADERSHIP
Bladder pain syndrome/interstitial cystitis (BPS/IC).
Phase 3 3Q 2018
Phase 2 trial did not meet endpoints - June 2015 but positive secondary endpoint data - August 2015. Phase 3 trial commenced September 2016. Data due 3Q 2018.
CNCE
$19.71
+0.1  (+0.5%)
AVP-786
Agitation in patients with Alzheimer's disease
Phase 3 3Q 2018
Phase 3 initiated December 2015. Trial to be completed 3Q 2018.
EIGR
$8.75
-0.1  (-1.13%)
Exendin 9-39
Post-Bariatric Hypoglycemia (PBH)
Phase 2 3Q 2018
Phase 2 data due 3Q 2018.
FLKS
$3.88
+0.03  (+0.77%)
FLX-787 - COMMEND US trial
Amyotrophic lateral sclerosis (ALS)
Phase 2 3Q 2018
Phase 2 start noted August 1, 2017. Data due 3Q 2018.
GILD
$81.41
+0.43  (+0.53%)
F/TAF (Descovy)
Pre-exposure prophylaxis
Phase 3 3Q 2018
Phase 3 trial to be completed 3Q 2018.
HSGX
$2.56
+0  (+0%)
NeoCart
Cartilage defects in the knee
Phase 3 3Q 2018
Phase 3 completion of enrollment announced June 27, 2017. Top-line data and potential BLA filing 3Q 2018.
NVO
$57.95
+0.16  (+0.27%)
Concizumab - explorer
Haemophilia A
Phase 2 3Q 2018
Phase 2 Explorer 5 data due 3Q 2018.
NVO
$57.95
+0.16  (+0.27%)
Somapacitan (NN8640) - REAL 3
Adult Growth Hormone Deficiency (AGHD)
Phase 3 3Q 2018
Phase 3 data due 3Q 2018.
PGNX
$6.52
+0.25  (+3.98%)
1404
Help visualize prostate cancer by targeting prostate specific membrane antigen (PSMA)
Phase 3 3Q 2018
Phase 3 completion of enrollment announced January 2, 2017. Top-line data due 3Q 2018.
RGLS
$1.39
-0.01  (-0.72%)
RG-012 - HERA
Alport Syndrome
Phase 2 3Q 2018
Phase 2 interim data due 3Q 2018.
TNXP
$4.04
+0.23  (+6.03%)
TNX-102 SL
Post-traumatic stress disorder (PTSD)
Phase 3 3Q 2018
Initiation of first of two Phase 3 trials announced March 28, 2017 in military-related PTSD 1Q 2017. Interim analysis due 3Q 2018 with top-line data due 4Q 2018.
URGN
$50.02
+7.02  (+16.32%)
MitoGel - OLYMPUS
Upper tract urothelial carcinoma (UTUC)
Phase 3 3Q 2018
Phase 3 enrollment commenced April 3, 2017. Top-line data due 3Q 2018.
VTL
$6.00
+0.5  (+9.09%)
VTI-308
Alcohol-induced liver decompensation, or AILD
Phase 3 3Q 2018
Phase 3 VTI-208 trial failed. New VTI-308 trial initiated May 2016. Data due 3Q 2018.
LLY
$85.44
-0.05  (-0.06%)
Galcanezumab - EVOLVE-1, EVOLVE-2 and REGAIN
Migraine prevention
PDUFA
BLA filing acceptance announced December 11, 2017. No PDUFA data supplied - estimate October 10, 2018.
PRTK
$16.20
+0.28  (+1.72%)
Sarecycline
Severe acne vulgaris
PDUFA 4Q 2018
PDUFA date 4Q 2018. Exact date not provided by company. Estimate October 19, 2018 based on NDA acceptance date of December 20, 2017.
MRK
$61.25
-0.03  (-0.05%)
Doravirine (MK-1439)
HIV
PDUFA
Phase 3 trial met primary endpoint - February 14, 2017. PDUFA date October 23, 2018.
TRVN
$1.75
+0  (+0%)
Oliceridine (TRV130)
Moderate to severe acute pain
PDUFA
Phase 3 APOLLO-1 and APOLLO-2 data released February 21, 2017 - primary endpoints met. PDUFA date November 2, 2018. Advisory Committee Meeting likely.
NVS
$87.00
+0.06  (+0.06%)
Adalimumab
Rheumatoid Arthritis
PDUFA Nov 16, 2018 est only
BLA filing acceptance announced January 16, 2018. No PDUFA date given - estimate November 16, 2018.
ABBV
$106.49
+1.85  (+1.76%)
ABT-494 - SELECT-COMPARE
Rheumatoid arthritis
Phase 3 2018
Phase 3 data due 2018.
ABBV
$106.49
+1.85  (+1.76%)
Imbruvica - PHOENIX
First-line Diffuse large B-cell lymphoma (DLBCL)
Phase 3 2018
Phase 3 data possibly due 2018.
ABUS
$5.15
-0.05  (-0.97%)
ARB-1467, tenofovir, and pegylated interferon
Hepatitis B (HBV)
Phase 2 2H 2018
Phase 2 interim data due 2H 2018 with full data due 2019.
ACIU
$13.51
+0.37  (+2.81%)
ACI-24 (anti-Abeta vaccine)
Alzheimer's disease-like characteristics in individuals with Down syndrome
Phase 1/2 2018
Phase 1/2 completion of recruitment of low-dose cohort noted September 12, 2017. Interim data due 2018.
ACRS
$24.79
+0.39  (+1.59%)
ATI-50002 - dose ranging
Alopecia areata
Phase 2 YE 2018
Phase 2 data due year-end 2018.
ADVM
$5.15
+0.25  (+5.1%)
ADVM-043
Alpha-1 Antitrypsin (A1AT) Deficiency
Phase 1/2 2H 2018
Phase 1/2 commencement of dosing announced December 28, 2017 with preliminary data due 2H 2018.
AGN
$188.15
+6.82  (+3.76%)
Brazikumab
Crohn's disease
Phase 2b 2018
Phase 2b data due 2018.
AGN
$188.15
+6.82  (+3.76%)
ABICIPAR
Age-related macular degeneration (AMD)
Phase 3 2H 2018
Phase 3 data due 2H 2018.
AIMT
$38.26
-0.64  (-1.65%)
AR101 RAMSES
Peanut Allergy
Phase 3 2H 2018
Phase 3 initiation announced May 11, 2017. Data due 2H 2018.
AKBA
$15.22
+0.51  (+3.46%)
Vadadustat - TRILO2GY
Three-times-weekly dosing regimen for vadadustat
Phase 3 YE 2018
Phase 3 trial to be initiated late 2017 or early 2018 with data due by the end of 2018.
AKBA
$15.22
+0.51  (+3.46%)
Vadadustat - FO2RWARD
Renal anemia
Phase 2 YE 2018
Phase 2 data due by the end of 2018.
AKCA
$18.53
+0.63  (+3.51%)
AKCEA-ANGPTL3-LRx
Rare hyperlipidemias
Phase 2 2018
Phase 2b initiation announced March 30, 2017. Data due 2018.
AKCA
$18.53
+0.63  (+3.51%)
AKCEA-APO(a)-LRx
Hyperlipoproteinemia(a) and established cardiovascular disease
Phase 2b 2018
Phase 2b initiation announced March 30, 2017. Data due 2018.
ALDX
$7.40
+0.5  (+7.24%)
ADX-102
Allergic conjunctivitis
Phase 2b 2H 2018
Phase 2b data released June 14 2017 - primary endpoint not met. However, Phase 3 trial is planned for 1H 2018 with data due 2H 2018.
ALDX
$7.40
+0.5  (+7.24%)
ADX-102
Noninfectious anterior uveitis
Phase 3 2H 2018
Phase 3 trial initiation announced April 27, 2017 with data due 2H 2018.
ALDX
$7.40
+0.5  (+7.24%)
ADX-102
Sjögren-Larsson Syndrome (SLS)
Phase 2 2H 2018
Phase 3 trial to be initiated 1H 2018 with initial data due 2H 2018.
ALNA
$9.43
-0.22  (-2.28%)
ALLN-177
Primary hyperoxaluria
Phase 2 2H 2018
Phase 2 trial to be initiated 1Q 2018 with interim data due 2H 2018.
ALNY
$131.00
+6.17  (+4.94%)
ALN-CC5 (cemdisiran)
Atypical hemolytic-uremic syndrome (aHUS)
Phase 1/2 2018
Phase 2 trial initiation announced September 26, 2017 with initial data due 2018.
ALXN
$123.67
+2.62  (+2.16%)
ALXN1210
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 1/2 2Q 2018
Phase 3 data due 2Q 2018.
APLS
$19.00
+0.1  (+0.52%)
APL-2 subcutaneous
Complement-dependent Nephropathies (CDN)
Phase 2 2H 2018
Phase 2 monotherapy data due 2H 2018.
ARGX
$66.25
-0.08  (-0.13%)
ARGX-113
Pemphigus vulgaris (PV)
Phase 2 2H 2018
Phase 2 initiation announced September 26, 2017 with interim data due 2H 2018.
ARGX
$66.25
-0.08  (-0.13%)
ARGX-113
Immune thrombocytopenia (ITP)
Phase 2 2H 2018
Phase 2 data due 2H 2018.
AST
$2.40
+0  (+0%)
AST-VAC2
Non-small cell lung cancer (NSCLC)
Phase 1/2 2H 2018
Phase 1/2 trial to be initiated 1H 2018 with initial safety and immunogenicity readouts due 2H 2018.
ATOS
$0.34
+0.01  (+4.12%)
Endoxifen
Breast cancer - patients who are not responding to Tamoxifen
Phase 2 2018
Phase 2 trial to be initiated 1Q 2018. Trial to be completed 2018.
ATOS
$0.34
+0.01  (+4.12%)
Endoxifen
Mammographic breast density (MBD)
Phase 2 2018
Phase 2 trial to be initiated 1Q 2018. Trial to be completed 2018.
AUPH
$5.80
+0.23  (+4.12%)
Voclosporin
Dry eye syndrome
Phase 2 2H 2018
Phase 2 trial to be initiated 2Q 2018 with data due 2H 2018.
AUPH
$5.80
+0.23  (+4.12%)
Voclosporin
Focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD)
Phase 2 2H 2018
Phase 2 trial to be initiated 1H 2018. Interim data readouts are anticipated 2H 2018.
AZN
$35.94
+0.5  (+1.41%)
Farxiga - DECLARE
Type-2 diabetes
Phase 3 2H 2018
Cardiovascular outcome data due 2H 2018.
AZN
$35.94
+0.5  (+1.41%)
Benralizumab - TERRANOVA
COPD
Phase 3 2H 2018
Phase 3 data due 2H 2018.
AZN
$35.94
+0.5  (+1.41%)
Durvalumab +/- tremelimumab (NEPTUNE)
Lung cancer
Phase 3 2H 2018
Phase 3 data due 2H 2018.
AZN
$35.94
+0.5  (+1.41%)
Anifrolumab
Lupus
Phase 3 2H 2018
Phase 3 data due 2H 2018.
BIIB
$347.64
+5.23  (+1.52%)
Raxatrigine - BIIB074 (Nav1.7 inhibitor)
Painful Lumbosacral Radiculopathy (PLSR)
Phase 2 2018
Phase 2 initiated 2016. Data due in 2018.
BIIB
$347.64
+5.23  (+1.52%)
BAN2401 (Aβ mAb)
Alzheimer’s disease
Phase 2 2H 2018
Phase 2 data due 2H 2018. Noted December 21, 2017 that Independent Data Monitoring Committee determined trial did not meet criteria for success.
BIVV
$103.79
+39.68  (+61.89%)
BIVV001 (EXTEN-A)
Hemophilia A
Phase 1/2 2018
Phase 1/2 readout due 2018.
BLPH
$2.41
+0.17  (+7.58%)
INOpulse delivery device
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)
Phase 2b YE 2018
Phase 2b enrollment announced January 3, 2018 with top-line data due by the end of 2018.
BLPH
$2.41
+0.17  (+7.58%)
INOpulse delivery device
Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF)
Phase 2 YE 2018
Phase 2 initiated May 2016. Data presented at American Thoracic Society (ATS) Conference, May 21 2017. Phase 2b planned for early 2018 with data due late 2018.
BLPH
$2.41
+0.17  (+7.58%)
INOpulse delivery device
Pulmonary Arterial Hypertension (PAH)
Phase 3 2018
Phase 3 commenced enrollment June 2016. Interim analysis and top-line data due 2018.
BLRX
$1.06
-0.03  (-2.76%)
BL-8040 in combination with KEYTRUDA - COMBAT trial
Pancreatic cancer
Phase 2
Phase 2 initiated September 2016. Partial data presented at ASCO 2018 Gastrointestinal Cancers Symposium, January 19, 2018. Full data due 2H 2018.
BLRX
$1.06
-0.03  (-2.76%)
BL-8040
Consolidation treatment for AML cancer patients
Phase 2b 2018
Phase 2b initiated August 2015. Interim analysis due in 2018, with top-line results expected in 2019.
BMY
$63.28
+1  (+1.6%)
CM-602 – Opdivo + Elo + SOC
Myeloma
Phase 3 2H 2018
Phase 3 data due 2H 2018. Noted September 6, 2017 that trial has been placed on partial hold.
BMY
$63.28
+1  (+1.6%)
CM-459 – Opdivo
First-line Hepatocellular carcinoma (HCC) - cancer
Phase 3 2H 2018
Phase 3 data due 2H 2018.
BMY
$63.28
+1  (+1.6%)
CM-451 – Opdivo + Yervoy
First-line Small cell lung cancer (SCLC)
Phase 3 2H 2018
Phase 3 data due 2H 2018.
BYSI
$28.21
+2.24  (+8.62%)
Plinabulin
Non small cell lung cancer - refractory
Phase 3 2018
Phase 3 trial initiated 2016. Interim data due 2018. Final data due 1Q 2019.
CANF
$1.81
+0.07  (+4.02%)
Namodenoson (CF102)
Cancer - advanced liver cancer second line
Phase 2 2H 2018
Phase 2 completion of enrollment announced August 9, 2017. Data due 2H 2018.
CASC
$4.59
+0.32  (+7.49%)
Tucatinib - MOUNTAINEER
HER2 amplified metastatic colorectal cancer
Phase 2 2018
Phase 2 trial initiated 3Q 2017. Interim data due 2018.
CELG
$102.91
+0.26  (+0.25%)
OTEZLA - SPSO-001
Scalp Psoriasis
Phase 3 2018
Phase 3 data due 2018.
CELG
$102.91
+0.26  (+0.25%)
REVLIMID - ROBUST
First-line ABC Diffuse large B-cell lymphoma (DLBCL)
Phase 3 2018
Phase 3 data due 2018.
CELG
$102.91
+0.26  (+0.25%)
MM-007 OPTIMISMM
Multiple Myeloma - refractory
Phase 3 2018
Phase 3 data due 2018.
CELG
$102.91
+0.26  (+0.25%)
Oral Azacitidine - CC-486-AML-001
Post induction AML Maintenance
Phase 3 2018
Phase 3 data due 2018.
CELG
$102.91
+0.26  (+0.25%)
ABRAXANE - PANC-003 apact
Adjuvant Therapy in Surgically Resected Pancreatic Cancer
Phase 3 YE 2018
Phase 3 data due year end 2018.
CELG
$102.91
+0.26  (+0.25%)
ABRAXANE - IMpower 130 ( I/O Combo)
Non-small cell lung cancer (NSCLC)
Phase 3 2018
Phase 3 data due 2018.
CELG
$102.91
+0.26  (+0.25%)
ABRAXANE - IMpower 131 ( I/O Combo)
Non-small cell lung cancer (NSCLC)
Phase 3 2018
Phase 3 data due 2018.
CELG
$102.91
+0.26  (+0.25%)
ABRAXANE - IMPassion ( I/O Combo)
Triple Negative Metastatic Breast Cancer
Phase 3 2018
Phase 3 data due 2018.
CFRX
$1.16
+0.04  (+3.57%)
CF-301
Serious infections caused byStaph aureus including MRSA
Phase 2 4Q 2018
Phase 2 initiation announced May 25, 2017 - data due 4Q 2018.
CMRX
$4.95
+0.02  (+0.4%)
IV Brincidofovir
Adenovirus
Phase 2 2H 2018
Phase 2 trial to be initiated 1H 2018 with data due 2H 2018.
CMTX
$10.00
+0  (+0%)
CX-2009 - PROCLAIM
Solid tumors
Phase 2 2H 2018
Phase 1/2 initial data due 2H 2018.
CNAT
$4.97
+0.26  (+5.52%)
Emricasan
NASH cirrhosis - ENCORE-PH trial
Phase 2 2H 2018
Phase 2b initiated November 2016. Data due 2H 2018.
CNCE
$19.71
+0.1  (+0.5%)
CTP-543
Alopecia areata
Phase 2a 2H 2018
Phase 2 clinical hold placed May 17, 2017 lifted July 10, 2017. Trial completion due 2H 2018.
CTMX
$26.30
+0.75  (+2.93%)
CX 2009
Solid tumors
Phase 1/2 2H 2018
Phase 1/2 initial data due 2H 2018.
DCPH
$27.90
+0.43  (+1.56%)
DCC-3014
Solid tumors or hematological malignancies
Phase 1 2H 2018
Phase 1 dose escalation initial data due 2H 2018.
EGRX
$60.58
+1.74  (+2.95%)
Fulvestrant
Breast cancer
Phase 3 4Q 2018
Pivotal trial initiation announced December 7, 2017. Trial completion and NDA filing due 4Q 2018.
EIGR
$8.75
-0.1  (-1.13%)
Ubenimex - ULTRA
Secondary lymphedema
Phase 2 2H 2018
Phase 2 completion of enrollment announced January 4, 2017. Data due 2H 2018.
EPZM
$16.40
+1.14  (+7.54%)
Tazemetostat
Adult patients with mesothelioma characterized by BAP1 loss-of-function
Phase 2 2018
Phase 2 dosing commenced August 2016. Enrollment completed June 2017 with data due 2018.
ESPR
$77.93
+0.73  (+0.94%)
Bempedoic Acid/ Ezetimibe (1002FDC-053)
Hypercholesterolemia
Phase 3 4Q 2018
Phase 3 initiation announced November 6, 2017. Data due 4Q 2018.
EVFM
$11.06
-0.62  (-5.31%)
Amphora - AMPOWER
contraceptive vaginal gel
Phase 3 4Q 2018
Phase 3 ongoing. Completion due 4Q 2018.
FGEN
$49.90
+2.04  (+4.28%)
Roxadustat - ANDES
Anaemia
Phase 3 2018
Phase 3 data due 2018.
FLKS
$3.88
+0.03  (+0.77%)
FLX-787
Amyotrophic lateral sclerosis (ALS)
Phase 2 2018
Phase 2 initiated September 2016. Readout due 2017/18.
FLXN
$23.29
-0.12  (-0.52%)
Zilretta - SHIP
Osteoarthritis of the Shoulder and Hip
Phase 2 2H 2018
Phase 2 trial initiation announced December 18, 2017. Top-line data due 2H 2018.
GEMP
$9.76
+1.59  (+19.46%)
Gemcabene - AZURE-1
Nonalcoholic steatohepatitis (NASH) / Nonalcoholic fatty liver disease (NAFLD)
Phase 2 2H 2018
Phase 2 trial initiation announced December 21, 2017. Top-line data due 2H 2018.
GILD
$81.41
+0.43  (+0.53%)
Tirabrutinib (GS-4059)
Chronic lymphocytic leukemia (CLL)
Phase 2 2H 2018
Phase 2 24-week endpoint due 2H 2018.
GILD
$81.41
+0.43  (+0.53%)
GS-9876
Sjogren’s syndrome
Phase 2 2H 2018
Phase 2 trial to be completed 2H 2018.
GILD
$81.41
+0.43  (+0.53%)
GS-5734
Ebola
Phase 2 2H 2018
Phase 2 trial to be completed 2H 2018.
GILD
$81.41
+0.43  (+0.53%)
Axicabtagene ciloleucel - KTE-C19 (ZUMA-2)
Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) - cancer
Phase 2 2018
Phase 2 pivotal initiated November 2015. Data due 2018.
GILD
$81.41
+0.43  (+0.53%)
Axicabtagene ciloleucel - KTE-C19 (ZUMA-3)
Adult patients with r/r ALL - cancer
Phase 1/2 2018
Phase 2 data due 2018. Phase 1 data released at ASCO June 5, 2017. Complete remission 73%. Data released at ASH 2017 showed complete remission of 71%.
GILD
$81.41
+0.43  (+0.53%)
Axicabtagene ciloleucel - KTE-C19 (ZUMA-4)
Pediatric and young adult patients with r/r ALL - cancer
Phase 1/2 2018
Phase 2 data due 2018.
GTHX
$25.35
-0.99  (-3.76%)
Trilaciclib
Triple-negative breast cancer
Phase 2 4Q 2018
Preliminary data due 4Q 2018.
GTXI
$13.35
+0.1  (+0.75%)
Enobosarm
Postmenopausal women with stress urinary incontinence (SUI)
Phase 2 YE 2018
Phase 2 data due by the end of 2018.
GWPH
$133.75
+1.33  (+1%)
Epidiolex
Dravet Syndrome
Phase 3 2H 2018
Second Phase 3 trial initiated mid April 2015. Data due 2H 2018.
GWPH
$133.75
+1.33  (+1%)
Epidiolex
Tuberous Sclerosis Complex
Phase 3 2H 2018
Phase 3 data due 2H 2018.
HALO
$18.95
+0.97  (+5.39%)
PEGPH20 - HALO-301
Pancreatic cancer
Phase 3 Late 4Q 2018
Phase 3 dosing initiated March 2016. PFS events due late 4Q 2018 with data to follow.
HALO
$18.95
+0.97  (+5.39%)
PEGPH20 in combination with KEYTRUDA
Non-small cell lung cancer (NSCLC)
Phase 1b 2018
Phase 1b enrollment resumed July 2016 under revised protocol. Data update due in 2018.
HTBX
$3.18
-0.22  (-6.48%)
HS-110 and nivolumab (Opdivo)
Non-small cell lung cancer (NSCLC)
Phase 1b 2H 2018
Phase 2 data due 2H 2018.
IMGN
$8.55
+0.52  (+6.47%)
Kadcyla (KATHERINE).
HER2-positive breast cancer - residual invasive disease
Phase 3 2018
Phase 3 data due in 2018.
IMRN
$7.01
-0.1  (-1.41%)
IMM-124E
Pediatric Nonalcoholic steatohepatitis (NASH)
Phase 2 4Q 2018
Phase 2 top-line data due 4Q 2018.
IMRN
$7.01
-0.1  (-1.41%)
IMM-529
C. difficile infection
Phase 1/2 4Q 2018
Phase 1/2 trial enrollment to commence mid-September 2017 with data due 4Q 2018.
INSY
$9.59
+0.9  (+10.35%)
Cannabidiol
Refractory childhood absence epilepsy
Phase 2 YE 2018
Phase 2 initiation announced December 19, 2017. Trial completion late 2018.
IOVA
$11.85
+1.14  (+10.74%)
LN-145
Cervical cancer
Phase 2 2018
Phase 2 dosing has commenced - noted August 16, 2017. Initial data due 2018.
JNJ
$148.14
+0.78  (+0.52%)
STELARA (USTEKINUMAB)
Ulcerative colitis
Phase 3 2018
Phase 3 trial to be completed in 2018.
JUNO
$86.00
+18.19  (+26.82%)
JCARH125
Multiple myeloma
Phase 1 2018
Phase 1 data due 2018.
KPTI
$10.27
+0.26  (+2.59%)
Selinexor - SADAL
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2b 2H 2018
Phase 2b additional interim data released June 23, 2017 at EHA. Final top-line data due 2H 2018.
LLY
$85.44
-0.05  (-0.06%)
Flortaucipir F 18 (Tau imaging agent)
Alzheimer's disease
Phase 3 2018
Phase 3 ongoing. Data due 2018 (internal readout).
MACK
$11.12
+0.3  (+2.77%)
MM-121 (SHERBOC)
HER2 negative metastatic breast cancer
Phase 2 2H 2018
Phase 2 data due 2H 2018.
MACK
$11.12
+0.3  (+2.77%)
MM-121
Cancer - Heregulin Positive Non-Small Cell Lung Cancer
Phase 2 2H 2018
Phase 2 initiated mid Feb 2015. Data due 2H 2018.
MBRX
$1.90
+0.05  (+2.7%)
Annamycin
Acute myeloid leukemia (AML) - cancer
Phase 1/2 2018
Phase 1/2 data due 2018.
MRNS
$7.55
+0.72  (+10.54%)
Ganaxolone
Refractory status epilepticus (RSE)
Phase 2 2018
Phase 2 data due 2018.
NBIX
$85.19
+4.51  (+5.59%)
INGREZZA - T-Force GOLD
Tourette syndrome - juvenile
Phase 2b Late-2018
Phase 2 data released May 23 - primary endpoint not met. Phase 2b trial initiation announced October 25, 2017. Top-line data due late 2018.
NCNA
$21.80
+1.29  (+6.28%)
NUC-3373
Solid tumors
Phase 1 2018
Phase 1 final data due 2018.
NCNA
$21.80
+1.29  (+6.28%)
NUC-1031 (Acelarin)
Platinum-sensitive ovarian cancer
Phase 2 2018
Phase 2 commencement of enrollment announced November 15, 2017. Interim data due 2018.
NITE
$14.39
-0.34  (-2.31%)
NSR-RPGR
X-linked Retinitis Pigmentosa
Phase 1/2 2018
Phase 1/2 preliminary data due 2018.
NVAX
$2.14
+0.17  (+8.62%)
RSV vaccine - prepare trial
Respiratory Syncytial Virus (RSV) in healthy pregnant women - protect infants via maternal immunization
Phase 3 4Q 2018 or 1Q 2019
Phase 3 initiated December 2015. Interim analysis due 4Q 2018 or 1Q 2019.
NVCR
$21.75
+0.65  (+3.08%)
Tumor Treating Fields (TTFields) STELLAR
Mesothelioma
Phase 2 2018
Phase 2 enrollment completion announced March 31, 2017. Data due 2018.
NVS
$87.00
+0.06  (+0.06%)
QVM149
Asthma
Phase 3 2018
Phase 3 data due 2018.
OBSV
$9.64
-0.09  (-0.93%)
OBE022 - PROLONG
Pre-term labor
Phase 2a YE 2018
Phase 2a trial initiation announced December 5, 2017. Part B preliminary data due late 2018.
OCUL
$6.48
+0.25  (+4.01%)
OTX-TP
Glaucoma and ocular hypertension
Phase 3 2H 2018
Phase 3 initiated October 2016. Data due 2H 2018.
ONCS
$2.10
+0.06  (+2.94%)
ImmunoPulse IL-12 - PISCES
Melanoma - cancer
Phase 2b 2018
Phase 2 initiation of dosing announced December 14, 2017 with initial data due 2018.
ONTX
$1.61
-0.16  (-9.04%)
IV Rigosertib - INSPIRE
2nd-line HR-MDS (high risk myelodysplastic syndromes)
Phase 3 2H 2018
Phase 3 trial recommended to continue by Data Monitoring Committee (DMC) following interim analysis January 17, 2018. Top-line data due 2H 2018.
OVID
$9.50
+0.32  (+3.48%)
OV101 (STARS)
Adults with Angelman syndrome
Phase 2 2H 2018
First patient randomized February 2017. Data due 2H 2018.
PIRS
$7.48
+0.06  (+0.8%)
PRS-080
Anemia of chronic disease
Phase 2a 2H 2018
Phase 2a trial initiated 3Q 2017. Data due 2H 2018.
PRQR
$3.03
+0.03  (+0.83%)
QR-010
Genetic blindness
Phase 1/2 2018
Phase 1/2 commencement of dosing announced November 14, 2017. Interim safety and efficacy 6-month data due 2018, full 12 month data due 2019.
PULM
$1.45
-0.03  (-2.03%)
PUR1800
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD)
Phase 2a 4Q 2018
Phase 2 data due 4Q 2018.
QURE
$19.71
+1.72  (+9.56%)
AMT-061
Hemophilia B
Phase 3 YE 2018
Pivotal trial to commence 3Q 2018 with initial data due by year-end 2018.
RARE
$53.39
+4.23  (+8.6%)
DTX301
Ornithine Transcarbamylase (OTC) Deficiency
Phase 1/2 2H 2018
Phase 1/2 initial from first cohort released January 7, 2018 with data from second cohort due 2H 2018.
RDHL
$5.33
+0.09  (+1.71%)
RHB-105 - ERADICATE Hp 2
H. pylori
Phase 3 2H 2018
Phase 3 final data released March 2016. Additional Phase 3 trial initiation announced June 15, 2017 with data due 2H 2018.
REGN
$375.86
+4.33  (+1.16%)
Dupixent (dupilumab)
Nasal polyps
Phase 3 2018
Phase 3 trial commenced 4Q 2016. Data due 2018.
RETA
$30.04
+0.25  (+0.83%)
Bardoxolone methyl - CATALYST
Pulmonary arterial hypertension associated with connective tissue disease - CTD-PAH
Phase 3 2H 2018
Phase 3 commenced enrollment October 2016 with data due 2H 2018.
RGNX
$27.40
+0.3  (+1.1%)
RGX-501
Homozygous familial hypercholesterolemia (HoFH)
Phase 1/2 Late 2018
Phase 1/2 dosing initiated - March 8, 2017. Top-line data due late 2018.
RIGL
$4.54
+0.31  (+7.32%)
Fostamatinib
IgA nephropathy
Phase 2 2018
Phase 2 preliminary data released January 5, 2017. Enrollment of second cohort to be completed in 2017 with data due in 2018.
RVNC
$34.25
+0.3  (+0.88%)
RT002 - SAKURA 1, 2 and 3
Moderate to severe glabellar (frown) lines
Phase 3 2H 2018
Phase 3 data released December 5, 2017 - endpoints met. SAKURA 3 Safety study to be completed 2H 2018 with BLA filing due 1H 2019.
SBBP
$8.45
-0.1  (-1.17%)
COR-003 (levoketoconazole) - LOGICS
Endogenous Cushing’s syndrome
Phase 3 4Q 2018
Phase 3 top-line data expected in 4Q 2018.
SCYX
$1.86
+0.01  (+0.54%)
SCY-078 - oral - CARES
Candida Auris
Phase 3 4Q 2018
Phase 3 open label preliminary review due 4Q 2018.
SCYX
$1.86
+0.01  (+0.54%)
SCY-078 - oral (FURI)
Invasive candidiasis
Phase 3 4Q 2018
Phase 3 open label trial commenced 3Q 2017. Preliminary data review 4Q 2018.
SGEN
$56.29
+2.81  (+5.25%)
ADCETRIS in combination with chemotherapy - ECHELON-2
Frontline CD30-positive mature T-cell lymphomas - cancer
Phase 3 2018
Phase 3 enrollment completed November 2016. Data are due in 2018.
SGMO
$19.40
+1.65  (+9.29%)
SB-FIX
Hemophilia B
Phase 1/2 2018
Phase 1/2 data due 2018.
SNNA
$19.47
+0.49  (+2.58%)
SNA-001
Reduction of light-pigmented hair
Phase 3 2H 2018
Pivotal data due 2H 2018.
SNNA
$19.47
+0.49  (+2.58%)
SNA-001
Acne
Phase 3 2H 2018
Pivotal data due 2H 2018.
SNY
$43.20
-1.4  (-3.14%)
Isatuximab
Refractory Multiple Myeloma
Phase 3 4Q 2018
Phase 3 trial initiated December 2016. Data due 4Q 2018.
SRPT
$65.65
+3.27  (+5.24%)
Microdystrophin gene therapy rAAVrh74.MCK.GALGT2
Duchenne muscular dystrophy
Phase 1/2 2H 2018
Phase 1/2 data due 2H 2018.
SRPT
$65.65
+3.27  (+5.24%)
GALGT2 gene therapy
Duchenne muscular dystrophy
Phase 1/2 2H 2018
Phase 1/2 data due 2H 2018.
SVRA
$13.04
+0.04  (+0.3%)
Molgradex - IMPALA
Autoimmune pulmonary alveolar proteinosis (PAP)
Phase 3 YE 2018
Phase 3 data due by the end of 2018.
TBPH
$29.64
+1.32  (+4.66%)
Closed Triple - CAPTAIN
Asthma
Phase 3 2H 2018
Phase 3 data due 2H 2018.
TCON
$2.95
+0.15  (+5.35%)
TRC105
Gestational Trophoblastic Neoplasia cancer
Phase 2 2018
Phase 2 planned for 2016. Data due 2018.
TCON
$2.95
+0.15  (+5.35%)
TRC102
Mesothelioma cancer
Phase 2 2018
Phase 2 initiated October 2015. Data are due in 2018.
TCON
$2.95
+0.15  (+5.35%)
TRC105 (TAPPAS)
Angiosarcoma cancer
Phase 3 2H 2018
Phase 3 dosage of first patient announced February 16, 2017. Interim analysis 2H 2018.
TSRO
$68.22
+4.3  (+6.74%)
Niraparib - AVANOVA
Ovarian cancer
Phase 1/2 2H 2018
Phase 1/2 data due 2H 2018.
UTHR
$143.46
+3.95  (+2.83%)
Esuberaprost - BEAT
Pulmonary arterial hypertension (PAH)
Phase 3 2018
Phase 3 enrollment has completed. Data possible 2018.
UTHR
$143.46
+3.95  (+2.83%)
Orenitram
Pulmonary arterial hypertension (PAH)
Phase 3 2H 2018
Phase 3 data due 2H 2018. Independent data monitoring committee (DMC) noted September 8, 2017 that the trial should continue following its interim analysis.
VNDA
$15.10
+0.6  (+4.13%)
Tradipitant
Gastroparesis
Phase 2 YE 2018
Phase 2 data due by end of 2018.
VNDA
$15.10
+0.6  (+4.13%)
HETLIOZ (tasimelteon)
Smith-Magenis Syndrome
Phase 3 2018
Phase 3 initiated 4Q 2016. Data due 2018.
XBIT
$4.76
+0.08  (+1.7%)
XBIO-101
Endometrial cancer
Phase 2 YE 2018
Phase 2 data due before the end of 2018.
XNCR
$22.67
+1.11  (+5.14%)
XmAb5871
Systemic Lupus Erythematosus (SLE)
Phase 2 4Q 2018
Phase 2 trial initiated March 2016. Initial data due 4Q 2018.
ZEAL
$15.32
+0.27  (+1.79%)
Dasiglucagon
Severe hypoglycemia in diabetes
Phase 3 2H 2018
Phase 3 trial initiated December 2017 with data due 2H 2018.
AIMT
$38.26
-0.64  (-1.65%)
AR101 ARTEMIS
Peanut Allergy
Phase 3 Early 2019
Phase 3 enrollment has commenced - noted June 5, 2017. Data due early 2019.
ASND
$53.69
+2.16  (+4.19%)
TransCon
Growth hormone deficiency in children
Phase 3 1Q 2019
Phase 3 completion of enrollment announced January 3, 2018. Data due 1Q 2019.
CLBS
$4.23
+0.12  (+2.91%)
CLBS03
Type 1 diabetes
Phase 2 Early 2019
Phase 2 completion of enrollment announced January 18, 2018 with top-line data due early 2019.
CLSD
$6.22
-0.22  (-3.42%)
Suprachoroidal CLS-TA - SAPPHIRE
Macular edema associated with retinal vein occlusion (RVO)
Phase 3 1Q 2019
Announced enrollment of the first patient in its Phase 3 trial - February 16, 2017. Preliminary data due 1Q 2019.
CLSN
$2.72
+0.05  (+1.87%)
ThermoDox - OPTIMA
Hepatocellular carcinoma - liver cancer
Phase 3 1Q 2019
Original Phase 3 trial failed to meet primary endpoint. New Phase 3 trial initiated with enrollment to be completed 3Q 2018 with first interim efficacy analysis due 1Q 2019.
CTXR
$4.37
+0.03  (+0.69%)
Mino-Lok
Catheter related blood stream infection
Phase 3 Early 2019
Phase 3 trial initiated 4Q 2017. To be completed early 2019.
GSK
$38.56
+0.36  (+0.94%)
Danirixin
Chronic obstructive pulmonary disease (COPD)
Phase 2b 1Q 2019
Phase 2b data likely due 1Q 2019.
ORMP
$8.59
+0.21  (+2.5%)
ORMD-0801
Type 2 Diabetes
Phase 2b Early 2019
Noted July 11, 2017 that an end of Phase 2 meeting scheduled with FDA for August 31, 2017. Company previously noted that Phase 2 top-line data endpoints were met in May, 2017. Data from additional Phase 2b trial due early 2019.
PRTO
$2.48
+0.03  (+1.02%)
Vonapanitase (PRT-201) PATENCY-2
Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)
Phase 3 1Q 2019
Phase 3 enrollment to be completed 1Q 2018. Data due 1Q 2019.
RNN
$2.41
+0.01  (+0.41%)
RX-3117 in combination with Abraxane
First-line pancreatic cancer
Phase 2a 1Q 2019
Phase 2 commencement of dosing announced November 8, 2017 with data due 1Q 2019.
ATRA
$33.35
+3.85  (+13.05%)
ATA188
Multiple sclerosis
Phase 1 1H 2019
Received clearance to initiate enrollment at US sites - January 10, 2018. Data due 1H 2019.
ATRA
$33.35
+3.85  (+13.05%)
ATA 129 - ALLELE
Epstein-Barr virus (EBV-PTLD) after solid organ transplant (SOT)
Phase 3 1H 2019
Phase 3 trial initiation announced January 3, 2017. Data due 1H 2019.
BMY
$63.28
+1  (+1.6%)
CM-568 - Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 2 2H 2018 – 1H 2019
Phase 2 data due 2H 2018 – 1H 2019.
CMRX
$4.95
+0.02  (+0.4%)
Oral Brincidofovir
Smallpox
1H 2019
Pivotal mouse trial to be initiated 2018 with data in 1H 2019.
CNAT
$4.97
+0.26  (+5.52%)
Emricasan
NASH fibrosis - ENCORE-NF trial
Phase 2 1H 2019
Phase 2 completion of enrollment noted August 14, 2017. Data are due 1H 2019.
FBIO
$3.96
+0  (+0%)
CEVA101
Severe Traumatic Brain Injury
Phase 2